

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
25 May 2001 (25.05.2001)

PCT

(10) International Publication Number  
**WO 01/36607 A1**

(51) International Patent Classification<sup>7</sup>: C12N 9/12,  
1/20, 15/00, C12Q 1/68, C07H 21/04

(21) International Application Number: PCT/US00/31622

(22) International Filing Date:  
17 November 2000 (17.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/166,179 18 November 1999 (18.11.1999) US

(71) Applicant: CORNELL RESEARCH FOUNDATION,  
INC. [US/US]; Cornell Business and Technology Park,  
Suite 105, 20 Thornwood Drive, Ithaca, NY 14850 (US).

(72) Inventor: LEI, Xingen; 114 Lexington Drive W., Ithaca,  
NY 14850 (US).

(74) Agents: GOLDMAN, Michael, L. et al.; Nixon Peabody  
LLP, Clinton Square, P.O. Box 31051, Rochester, NY  
14603 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- With international search report.
- Before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments.

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: SITE-DIRECTED MUTAGENESIS OF *ESCHERICHIA COLI* PHYTASE

(57) Abstract: The present invention relates to an isolated mutant acid phosphatase/phytase with improved enzymatic properties. The mutant acid phosphatase/phytase composition is particularly useful in animal feed compositions.



WO 01/36607 A1

- 1 -

## SITE-DIRECTED MUTAGENESIS OF *ESCHERICHIA COLI* PHYTASE

The present application claims the benefit of U.S. Provisional  
5 Patent Application Serial No. 60/166,179, filed November 18, 1999.

### FIELD OF THE INVENTION

The present invention is directed to the site-directed mutagenesis of  
*Escherichia coli* phosphatase/phytase.

10

### BACKGROUND OF THE INVENTION

Phytases, a specific group of monoester phosphatases, are required  
to initiate the release of phosphate ("P") from phytate (myo-inositol  
hexophosphate), the major storage form of P in cereal foods or feeds (Reddy, N.R.  
15 et al., "Phytates in Legumes and Cereals," Advances in Food Research, 28:1  
(1982)). Because simple-stomached animals like swine and poultry as well as  
humans have little phytase activity in their gastrointestinal tracts, nearly all of the  
ingested phytate P is indigestible. This results in the need for supplementation of  
inorganic P, an expensive and non-renewable nutrient, in diets for these animals.  
20 More undesirably, the unutilized phytate-P excreted through manure of these  
animals becomes P pollution of the environment (Cromwell, G.L. et al., "P- A  
Key Essential Nutrient, Yet a Possible Major Pollutant -- Its Central Role in  
Animal Nutrition," Biotechnology In the Feed Industry; Proceedings Alltech 7th  
Annual Symposium, p. 133 (1991)). Furthermore, phytate chelates with essential  
25 trace elements like zinc and produces nutrient deficiencies such as growth and  
mental retardation in children ingesting mainly plant origin foods without removal  
of phytate.

Two phytases, *phyA* and *phyB*, from *Aspergillus niger* NRRL3135  
have been cloned and sequenced (Ehrlich, K.C. et al., "Identification and Cloning  
30 of a Second Phytase Gene (*phys*) from *Aspergillus niger* (*ficuum*)," Biochem.  
Biophys. Res. Commun., 195:53-57 (1993); Piddington, C.S. et al., "The Cloning  
and Sequencing of the Genes Encoding Phytase (*phy*) and pH 2.5-optimum Acid

Phosphatase (*aph*) from *Aspergillus niger* var. *awamori*," Gene, 133:56-62 (1993)). Recently, new phytase genes have been isolated from *Aspergillus terreus* and *Myceliophthora thermophila* (Mitchell et al., "The Phytase Subfamily of Histidine Acid Phosphatases: Isolation of Genes for Two Novel Phytases From the Fungi *Aspergillus terreus* and *Myceliophthora thermophila*," Microbiology 143:245-52, (1997)), *Aspergillus fumigatus* (Pasamontes et al., "Gene Cloning, Purification, and Characterization of a Heat-Stable Phytase from the Fungus *Aspergillus fumigatus*" Appl. Environ. Microbiol., 63:1696-700 (1997)), *Emmericella nidulans* and *Talaromyces thermophilus* (Pasamontes et al., "Cloning of the Phytase from *Emmericella nidulans* and the Thermophilic Fungus *Talaromyces thermophilus*," Biochim. Biophys. Acta., 1353:217-23 (1997)), and maize (Maugnest et al., "Cloning and Characterization of a cDNA Encoding a Maize Seedling Phytase," Biochem. J. 322:511-17 (1997)).

Various types of phytase enzymes have been isolated and/or purified from *Enterobacter sp. 4* (Yoon et al., "Isolation and Identification of Phytase-Producing Bacterium, *Enterobacter sp. 4*, and Enzymatic Properties of Phytase Enzyme," Enzyme and Microbial Technology 18:449-54 (1996)), *Klebsiella terrigena* (Greiner et al., "Purification and Characterization of a Phytase from *Klebsiella terrigena*," Arch. Biochem. Biophys. 341:201-06 (1997)), and *Bacillus sp. DS11* (Kim et al., "Purification and Properties of a Thermostable Phytase from *Bacillus sp. DS11*," Enzyme and Microbial Technology 22:2-7 (1998)). Properties of these enzyme have been studied. In addition, the crystal structure of phyA from *Aspergillus ficuum* has been reported (Kostrewa et al., "Crystal Structure of Phytase from *Aspergillus ficuum* at 2.5 Å Resolution," Nature Structure Biology 4:185-90 (1997)).

Hartingsveldt et al. introduced *phyA* gene into *A. niger* and obtained a ten-fold increase of phytase activity compared to the wild type. ("Cloning, Characterization and Overexpression of the Phytase-Encoding Gene (*phyA*) of *Aspergillus Niger*," Gene 127:87-94 (1993)). Supplemental microbial phytase of this source in the diets for pigs and poultry has been shown to be effective in improving utilization of phytate-P and zinc (Simons et al., "Improvement of Phosphorus Availability By Microbial Phytase in Broilers and

- 3 -

Pigs," Br. J. Nutr., 64:525 (1990); Lei, X.G. et al., "Supplementing Corn-Soybean Meal Diets With Microbial Phytase Linearly Improves Phytate P Utilization by Weaning Pigs," J. Anim. Sci., 71:3359 (1993); Lei, X.G. et al., "Supplementing Corn-Soybean Meal Diets With Microbial Phytase Maximizes Phytate P Utilization by Weaning Pigs," J. Anim. Sci., 71:3368 (1993); Cromwell, G.L. et al., "P- A Key Essential Nutrient, Yet a Possible Major Pollutant -- Its Central Role in Animal Nutrition," Biotechnology In the Feed Industry; Proceedings Alltech 7th Annual Symposium, p. 133 (1991)). However, the cost of the limited commercial phytase supply and its instability when subjected to heat during feed pelleting preclude its practical use in animal industry (Jongbloed, A.W. et al., "Effect of Pelleting Mixed Feeds on Phytase Activity and Apparent Absorbability of Phosphorus and Calcium in Pigs," Animal Feed Science and Technology, 28:233-42 (1990)). Moreover, phytase produced from *A. niger* is presumably not the safest source for human food manufacturing.

Thus, there is a need to improve phytase production for application by the food and feed industry.

### SUMMARY OF THE INVENTION

The present invention relates to an isolated mutant acid phosphatase/phytase which is produced by making a plurality of amino acid substitutions in a wild-type *Escherichia coli* acid phosphatase/phytase having an amino acid sequence of SEQ. ID. No. 1. These amino acid substitutions are made at positions 200, 207, and 211 of SEQ. ID. No. 1. The present invention also involves an isolated mutant acid phosphatase/phytase which differs from the wild-type acid phosphatase/phytase having an amino acid sequence of SEQ. ID. No. 1 by at least one amino acid substitution which disrupts disulfide bond formation between Cys amino acid residues at positions 200 and 210. The mutant acid phosphatase/phytase of the present invention is useful in animal feed compositions.

The present invention also relates to a method for improving the enzymatic properties of a wild-type *Escherichia coli* acid phosphatase/phytase

- 4 -

having an amino acid sequence of SEQ. ID. No. 1. This method involves altering the amino acid sequence of the wild-type acid phosphatase/phytase by introducing amino acid substitutions into SEQ. ID. No. 1 at positions 200, 207, and 211.

Another embodiment of this method involves altering the amino acid sequence of the wild-type acid phosphatase/phytase having SEQ. ID. No. 1 by introducing at least one amino acid substitution which disrupts disulfide bond formation between Cys amino acid residues at positions 200 and 210.

Another aspect of this invention relates to an isolated DNA molecule which encodes the mutant acid phosphatase/phytase of the present invention. Also disclosed are recombinant DNA expression systems and host cells containing the DNA molecule of the present invention. These constructions can be used to recombinantly produce the mutant acid phosphatase/phytase of the present invention.

The invention also provides a basic molecular method that can be broadly applied to design mutant acid phosphatases/phytases derived from various source organisms, resulting in mutants with enhanced enzymatic properties such as greater thermostability and catalytic efficiency. This method includes identifying and isolating a gene of a wild-type enzyme and using this gene as the object of site-directed mutagenesis in order to enhance the enzyme's function and/or stability. One aspect of this invention is to use site-directed mutagenesis to make targeted mutations to the wild-type gene in order to add N-glycosylation sites to the wild-type enzyme and/or to alter the enzyme's physiochemical properties (e.g., increasing the net positive charge of the enzyme). In addition, targeted mutations can be made to the wild-type gene in order to eliminate certain disulfide bonds found in the final protein product, resulting in enhanced thermostability and catalytic function.

### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the nucleotide (SEQ. ID. No. 2) and the deduced amino acid (SEQ. ID. No. 1) sequence of the *E. coli* acid phosphatase/phytase (appA). Primers are underlined and indicated by arrows. The GH loop region

- 5 -

(202-211) is in bold and C200 (in G helix) and C210 (in GH loop) form the unique disulfide bond in the  $\alpha$ -domain. Substituted amino acids (A131, V134N, C200, D207, and S211) are underlined and in bold.

Figure 2 shows an SDS-gel electrophoresis (15%) analysis of purified recombinant proteins expressed in *Pichia pastoris*. Thirty micrograms of protein was loaded per lane. Lane M, prestained marker (Biorad, kDa) (phosphorylase *b*, 103; bovine serum albumin, 76; ovalbumin, 49; carbonic anhydrase, 33.2; soybean trypsin inhibitor, 28); Lane 1, Endo H<sub>f</sub> (endoglycosidase H<sub>f</sub>); Lane 2, r-AppA (recombinant protein produced by *appA* in *Pichia pastoris*); Lane 3, r-AppA + Endo H<sub>f</sub>; Lane 4, Mutant U; Lane 5, Mutant U + Endo H<sub>f</sub>; Lane 6, Mutant R; Lane 7, Mutant R + Endo H<sub>f</sub>; Lane 8, Mutant Y; Lane 9, Mutant Y + Endo H<sub>f</sub>.

Figure 3 shows the pH dependence of the enzymatic activity at 37°C of the purified r-AppA (●) and Mutants (U, ■; Y, ▲, R, ◆) using sodium phytate as a substrate. The maximal activity for each mutant and r-AppA was defined as 100%. Buffers: pH 1.5-3.5, 0.2 M glycine-HCl; pH 4.5-7.5, 0.2 M sodium citrate; pH 8.5-11, 0.2 M Tris-HCl. Asterisks indicate significant differences ( $P < 0.05$ ) between r-AppA and other mutants. Results are expressed as the mean  $\pm$  SE from three experiments.

Figure 4 shows the residual enzymatic activity of the purified r-AppA (●) and Mutants (U, ■; Y, ▲; R, ◆) after exposure for 15 min at the indicated temperature. The purified enzyme was incubated for 15 min in 0.2 M glycine-HCl, pH 2.5. At the end of heating, the reaction mixture was cooled on ice for 30 min. The initial activity with sodium phytate for each recombinant enzyme was defined as 100%. Asterisks indicate significant differences ( $P < 0.05$ ) between r-AppA and other mutants. Results are expressed as the mean  $\pm$  SE from three experiments.



- 6 -

# DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to an isolated mutant acid phosphatase/phytase which is produced by site-directed mutagenesis of a wild-type *Escherichia coli* acid phosphatase/phytase. According to one embodiment, the mutant acid phosphatase/phytase is made by introducing a plurality of targeted amino acid substitutions in a wild-type *Escherichia coli* acid phosphatase/phytase. In another embodiment, the mutant acid phosphatase/phytase is produced by introducing at least one amino acid substitution into the wild-type acid phosphatase/phytase in order to disrupt disulfide bond formation between Cys amino acid residues of the mutant acid phosphatase/phytase. The wild-type acid phosphatase/phytase has an amino acid sequence corresponding to SEQ. ID. No. 1 as follows:

15	Met	Lys	Ala	Ile	Leu	Ile	Pro	Phe	Leu	Ser	Leu	Leu	Ile	Pro	Leu	Thr	1	5	10	15
	Pro	Gln	Ser	Ala	Phe	Ala	Gln	Ser	Glu	Pro	Glu	Leu	Lys	Leu	Glu	Ser	20	25	30	
20	Val	Val	Ile	Val	Ser	Arg	His	Gly	Val	Arg	Ala	Pro	Thr	Lys	Ala	Thr	35	40	45	
	Gln	Leu	Met	Gln	Asp	Val	Thr	Pro	Asp	Ala	Trp	Pro	Thr	Trp	Pro	Val	50	55	60	
25	Lys	Leu	Gly	Trp	Leu	Thr	Pro	Arg	Gly	Gly	Glu	Leu	Ile	Ala	Tyr	Leu	65	70	75	80
	Gly	His	Tyr	Gln	Arg	Gln	Arg	Leu	Val	Ala	Asp	Gly	Leu	Leu	Ala	Lys	85	90	95	
30	Lys	Gly	Cys	Pro	Gln	Pro	Gly	Gln	Val	Ala	Ile	Ile	Ala	Asp	Val	Asp	100	105	110	
35	Glu	Arg	Thr	Arg	Lys	Thr	Gly	Glu	Ala	Phe	Ala	Ala	Gly	Leu	Ala	Pro	115	120	125	
	Asp	Cys	Ala	Ile	Thr	Val	His	Thr	Gln	Ala	Asp	Thr	Ser	Ser	Pro	Asp	130	135	140	
40	Pro	Leu	Phe	Asn	Pro	Leu	Lys	Thr	Gly	Val	Cys	Gln	Leu	Asp	Asn	Ala	145	150	155	160
	Asn	Val	Thr	Asp	Ala	Ile	Leu	Ser	Arg	Ala	Gly	Gly	Ser	Ile	Ala	Asp	165	170	175	
45	Phe	Thr	Gly	His	Arg	Gln	Thr	Ala	Phe	Arg	Glu	Leu	Glu	Arg	Val	Leu	180	185	190	

- 7 -

	Asn	Phe	Pro	Gln	Ser	Asn	Leu	Cys	Leu	Lys	Arg	Glu	Lys	Gln	Asp	Glu	
			195					200					205				
5	Ser	Cys	Ser	Leu	Thr	Gln	Ala	Leu	Pro	Ser	Glu	Leu	Lys	Val	Ser	Ala	
		210					215					220					
	Asp	Asn	Val	Ser	Leu	Thr	Gly	Ala	Val	Ser	Leu	Ala	Ser	Met	Leu	Thr	
	225					230					235					240	
10	Glu	Ile	Phe	Leu	Leu	Gln	Gln	Ala	Gln	Gly	Met	Pro	Glu	Pro	Gly	Trp	
					245					250					255		
	Gly	Arg	Ile	Thr	Asp	Ser	His	Gln	Trp	Asn	Thr	Leu	Leu	Ser	Leu	His	
				260					265					270			
15	Asn	Ala	Gln	Phe	Tyr	Leu	Leu	Gln	Arg	Thr	Pro	Glu	Val	Ala	Arg	Ser	
			275					280					285				
	Arg	Ala	Thr	Pro	Leu	Leu	Asp	Leu	Ile	Lys	Thr	Ala	Leu	Thr	Pro	His	
20		290					295					300					
	Pro	Pro	Gln	Lys	Gln	Ala	Tyr	Gly	Val	Thr	Leu	Pro	Thr	Ser	Val	Leu	
	305					310					315					320	
25	Phe	Ile	Ala	Gly	His	Asp	Thr	Asn	Leu	Ala	Asn	Leu	Gly	Gly	Ala	Leu	
					325					330					335		
	Glu	Leu	Asn	Trp	Thr	Leu	Pro	Gly	Gln	Pro	Asp	Asn	Thr	Pro	Pro	Gly	
				340					345					350			
30	Gly	Glu	Leu	Val	Phe	Glu	Arg	Trp	Arg	Arg	Leu	Ser	Asp	Asn	Ser	Gln	
			355					360					365				
	Trp	Ile	Gln	Val	Ser	Leu	Val	Phe	Gln	Thr	Leu	Gln	Gln	Met	Arg	Asp	
35		370					375					380					
	Lys	Thr	Pro	Leu	Ser	Leu	Asn	Thr	Pro	Pro	Gly	Glu	Val	Lys	Leu	Thr	
	385					390					395					400	
40	Leu	Ala	Gly	Cys	Glu	Glu	Arg	Asn	Ala	Gln	Gly	Met	Cys	Ser	Leu	Ala	
					405					410					415		
	Gly	Phe	Thr	Gln	Ile	Val	Asn	Glu	Ala	Arg	Ile	Pro	Ala	Cys	Ser	Leu *	
				420					425					430			
45																	

The wild-type acid phosphatase/phytase having the amino acid sequence according to SEQ. ID. No. 1 is encoded by the coding sequence of bases 187-1486 of the nucleotide sequence of SEQ. ID. No. 2 as follows:

1	taa gga gca gaa aca ATG TGG TAT TTA CTT TGG TTC GTC GGC ATT
50	
46	TTG TTG ATG TGT TCG CTC TCC ACC CTT GTG TTG GTA TGG CTG GAC
91	CCG CGA TTG AAA AGT T aac gaa cgt agg cct gat gcg gcg cat
55	134 tag cat cgc atc agg caa tca ata atg tca gat atg aaa agc gga



- 8 -

179 aac ata tcg ATG AAA GCG ATC TTA ATC CCA TTT TTA TCT CTT CTG  
5 224 ATT CCG TTA ACC CCG CAA TCT GCA TTC GCT CAG AGT GAG CCG GAG  
269 CTG AAG CTG GAA AGT GTG GTG ATT GTC AGC CGT CAT GGT GTG CGT  
314 GCC CCA ACC AAG GCC ACG CAA CTG ATG CAG GAT GTC ACC CCA GAC  
10 359 GCA TGG CCA ACC TGG CCG GTA AAA CTG GGT TGG CTG ACA CCA CGC  
404 GGT GGT GAG CTA ATC GCC TAT CTC GGA CAT TAC CAA CGC CAG CGT  
15 449 CTG GTG GCC GAC GGA TTG CTG GCG AAA AAG GGC TGC CCG CAG CCT  
494 GGT CAG GTC GCG ATT ATT GTC GAT GTC GAC GAG CGT ACC CGT AAA  
539 ACA GGC GAA GCC TTC GCC GCC GGG CTG GCA CCT GAC TGT GCA ATA  
20 584 ACC GTA CAT ACC CAG GCA GAT ACG TCC AGT CCC GAT CCG TTA TTT  
629 ATT CCT CTA AAA ACT GGC GTT TGC CAA CTG GAT AAC GCG AAC GTG  
25 674 ACT GAC GCG ATC CTC AGC AGG GCA GGA GGG TCA ATT GCT GAC TTT  
719 ACC GGG CAT CGG CAA ACG GCG TTT CGC GAA CTG GAA CGG GTG CTT  
764 AAT TTT CCG CAA TCA AAC TTG TGC CTT AAA CGT GAG AAA CAG GAC  
30 809 GAA AGC TGT TCA TTA ACG CAG GCA TTA CCA TCG GAA CTC AAG GTG  
854 AGC GCC GAC AAT GTT TCA TTA ACC GGT GCG GTA AGC CTC GCA TCA  
35 899 ATG CTG ACG GAA ATA TTT CTC CTG CAA CAA GCA CAG GGA ATG CCG  
944 GAG CCG GGG TGG GGA AGG ATC ACT GAT TCA CAC CAG TGG AAC ACC  
989 TTG CTA AGT TTG CAT AAC GCG CAA TTT TAT TTA CTA CAA CGC ACG  
40 1034 CCA GAG GTT GCC CGC AGT CGC GCC ACC CCG TTA TTG GAT TTG ATC  
1079 AAG ACA GCG TTG ACG CCC CAT CCA CCG CAA AAA CAG GCG TAT GGT  
1124 GTG ACA TTA CCC ACT TCA GTG CTG TTT ATT GCC GGA CAC GAT ACT  
45 1169 AAT CTG GCA AAT CTC GGC GGC GCA CTG GAG CTC AAC TGG ACG CTT  
1214 CCA GGT CAG CCG GAT AAC ACG CCG CCA GGT GGT GAA CTG GTG TTT  
50 1259 GAA CGC TGG CGT CGG CTA AGC GAT AAC AGC CAG TGG ATT CAG GTT  
1304 TCG CTG GTC TTC CAG ACT TTA CAG CAG ATG CGT GAT AAA ACG CCG  
1349 CTA TCA TTA AAT ACG CCG CCC GGA GAG GTG AAA CTG ACC CTG GCA  
55 1394 GGA TGT GAA GAG CGA AAT GCG CAG GGC ATG TGT TCG TTG GCC GGT  
1439 TTT ACG CAA ATC GTG AAT GAA GCG CGC ATA CCG GCG TGC AGT TTG  
60 1484 TAA

- 9 -

This acid phosphatase/phytase is derived from *E. coli*.

In producing the mutant acid phosphatase/phytase of the present invention, amino acid substitutions are made at positions 200, 207, and 211 of SEQ. ID. No. 1. It is particularly preferred to have the amino acid substitutions in the acid phosphatase/phytase of SEQ. ID. No. 1 be as follows: at position 200, be an Asn amino acid residue instead of a Cys amino acid residue; at position 207, be an Asn amino acid residue instead of an Asp amino acid residue; and at position 211, be an Asn amino acid residue instead of a Ser amino acid residue. As a result, the mutant acid phosphatase/phytase has an amino acid sequence of SEQ. ID. No. 3 as follows (the amino acid substitutions are underlined and in bold):

	Met	Lys	Ala	Ile	Leu	Ile	Pro	Phe	Leu	Ser	Leu	Leu	Ile	Pro	Leu	Thr	
	1				5					10					15		
15	Pro	Gln	Ser	Ala	Phe	Ala	Gln	Ser	Glu	Pro	Glu	Leu	Lys	Leu	Glu	Ser	
				20					25					30			
	Val	Val	Ile	Val	Ser	Arg	His	Gly	Val	Arg	Ala	Pro	Thr	Lys	Ala	Thr	
			35					40					45				
20	Gln	Leu	Met	Gln	Asp	Val	Thr	Pro	Asp	Ala	Trp	Pro	Thr	Trp	Pro	Val	
		50					55					60					
	Lys	Leu	Gly	Trp	Leu	Thr	Pro	Arg	Gly	Gly	Glu	Leu	Ile	Ala	Tyr	Leu	
25	65					70				75						80	
	Gly	His	Tyr	Gln	Arg	Gln	Arg	Leu	Val	Ala	Asp	Gly	Leu	Leu	Ala	Lys	
				85						90					95		
30	Lys	Gly	Cys	Pro	Gln	Pro	Gly	Gln	Val	Ala	Ile	Ile	Ala	Asp	Val	Asp	
				100					105					110			
	Glu	Arg	Thr	Arg	Lys	Thr	Gly	Glu	Ala	Phe	Ala	Ala	Gly	Leu	Ala	Pro	
			115					120					125				
35	Asp	Cys	Ala	Ile	Thr	Val	His	Thr	Gln	Ala	Asp	Thr	Ser	Ser	Pro	Asp	
		130					135					140					
	Pro	Leu	Phe	Asn	Pro	Leu	Lys	Thr	Gly	Val	Cys	Gln	Leu	Asp	Asn	Ala	
40	145					150				155						160	
	Asn	Val	Thr	Asp	Ala	Ile	Leu	Ser	Arg	Ala	Gly	Gly	Ser	Ile	Ala	Asp	
				165					170						175		
45	Phe	Thr	Gly	His	Arg	Gln	Thr	Ala	Phe	Arg	Glu	Leu	Glu	Arg	Val	Leu	
			180					185						190			
	Asn	Phe	Pro	Gln	Ser	Asn	Leu	<u>Asn</u>	Leu	Lys	Arg	Glu	Lys	Gln	<u>Asn</u>	Glu	
		195						200					205				

50

- 10 -

	Ser	Cys	<u>Asn</u>	Leu	Thr	Gln	Ala	Leu	Pro	Ser	Glu	Leu	Lys	Val	Ser	Ala	
	210						215					220					
5	Asp	Asn	Val	Ser	Leu	Thr	Gly	Ala	Val	Ser	Leu	Ala	Ser	Met	Leu	Thr	
	225					230					235				240		
	Glu	Ile	Phe	Leu	Leu	Gln	Gln	Ala	Gln	Gly	Met	Pro	Glu	Pro	Gly	Trp	
					245					250					255		
10	Gly	Arg	Ile	Thr	Asp	Ser	His	Gln	Trp	Asn	Thr	Leu	Leu	Ser	Leu	His	
				260					265					270			
	Asn	Ala	Gln	Phe	Tyr	Leu	Leu	Gln	Arg	Thr	Pro	Glu	Val	Ala	Arg	Ser	
15			275					280					285				
	Arg	Ala	Thr	Pro	Leu	Leu	Asp	Leu	Ile	Lys	Thr	Ala	Leu	Thr	Pro	His	
	290						295					300					
20	Pro	Pro	Gln	Lys	Gln	Ala	Tyr	Gly	Val	Thr	Leu	Pro	Thr	Ser	Val	Leu	
	305					310					315					320	
	Phe	Ile	Ala	Gly	His	Asp	Thr	Asn	Leu	Ala	Asn	Leu	Gly	Gly	Ala	Leu	
					325					330					335		
25	Glu	Leu	Asn	Trp	Thr	Leu	Pro	Gly	Gln	Pro	Asp	Asn	Thr	Pro	Pro	Gly	
				340					345					350			
	Gly	Glu	Leu	Val	Phe	Glu	Arg	Trp	Arg	Arg	Leu	Ser	Asp	Asn	Ser	Gln	
30			355					360					365				
	Trp	Ile	Gln	Val	Ser	Leu	Val	Phe	Gln	Thr	Leu	Gln	Gln	Met	Arg	Asp	
	370						375					380					
35	Lys	Thr	Pro	Leu	Ser	Leu	Asn	Thr	Pro	Pro	Gly	Glu	Val	Lys	Leu	Thr	
	385					390					395				400		
	Leu	Ala	Gly	Cys	Glu	Glu	Arg	Asn	Ala	Gln	Gly	Met	Cys	Ser	Leu	Ala	
				405						410					415		
40	Gly	Phe	Thr	Gln	Ile	Val	Asn	Glu	Ala	Arg	Ile	Pro	Ala	Cys	Ser	Leu *	
				420					425					430			

The mutant acid phosphatase/phytase of SEQ. ID. No. 3 has a molecular mass of 45 to 48 kDa, after deglycosylation, and has a specific phytase activity of 63 U/mg. The mature protein is represented by the amino acid sequence of amino acids 21-432 of SEQ. ID. No. 3.

Another aspect of the present invention involves producing a mutant acid phosphatase/phytase by inserting at least one amino acid substitution into the amino acid sequence of SEQ. ID. No. 1 in order to disrupt disulfide bond formation in the mutant acid phosphatase/phytase. In particular, targeted

- 11 -

substitution of the Cys amino acid residue at positions 200 and/or 210 of SEQ. ID. No. 1 can be made in order to eliminate the disulfide bond between these residues.

The mutant acid phosphatase/phytase having an amino acid sequence according to SEQ. ID. No. 3 is encoded by the coding sequence of bases 187-1486 of the nucleotide sequence of SEQ. ID. No. 4 as follows (the codons for the substituted Asn residues at amino acid positions 200, 207, and 211 are underlined and in bold):

```

1      taa gga gca gaa aca ATG TGG TAT TTA CTT TGG TTC  GTC GGC ATT
10    46    TTG TTG ATG TGT TCG CTC TCC ACC CTT GTG TTG GTA  TGG CTG GAC
      91    CCG CGA TTG AAA AGT T aac gaa cgt agg cct gat gcg gcg cat
      134   tag cat cgc atc agg caa tca ata atg tca gat atg  aaa agc gga
15    179   aac ata tcg ATG AAA GCG ATC TTA ATC CCA TTT TTA  TCT CTT CTG
      224   ATT CCG TTA ACC CCG CAA TCT GCA TTC GCT CAG AGT  GAG CCG GAG
20    269   CTG AAG CTG GAA AGT GTG GTG ATT GTC AGC CGT CAT  GGT GTG CGT
      314   GCC CCA ACC AAG GCC ACG CAA CTG ATG CAG GAT GTC  ACC CCA GAC
      359   GCA TGG CCA ACC TGG CCG GTA AAA CTG GGT TGG CTG  ACA CCA CGC
25    404   GGT GGT GAG CTA ATC GCC TAT CTC GGA CAT TAC CAA  CGC CAG CGT
      449   CTG GTG GCC GAC GGA TTG CTG GCG AAA AAG GGC TGC  CCG CAG CCT
30    494   GGT CAG GTC GCG ATT ATT GTC GAT GTC GAC GAG CGT  ACC CGT AAA
      539   ACA GGC GAA GCC TTC GCC GCC GGG CTG GCA CCT GAC  TGT GCA ATA
      584   ACC GTA CAT ACC CAG GCA GAT ACG TCC AGT CCC GAT  CCG TTA TTT
35    629   ATT CCT CTA AAA ACT GGC GTT TGC CAA CTG GAT AAC  GCG AAC GTG
      674   ACT GAC GCG ATC CTC AGC AGG GCA GGA GGG TCA ATT  GCT GAC TTT
40    719   ACC GGG CAT CGG CAA ACG GCG TTT CGC GAA CTG GAA  CGG GTG CTT
      764   AAT TTT CCG CAA TCA AAC TTG AAC CTT AAA CGT GAG  AAA CAG AAT
      809   GAA AGC TGT AAC TTA ACG CAG GCA TTA CCA TCG GAA  CTC AAG GTG
45    854   AGC GCC GAC AAT GTT TCA TTA ACC GGT GCG GTA AGC  CTC GCA TCA
      899   ATG CTG ACG GAA ATA TTT CTC CTG CAA CAA GCA CAG  GGA ATG CCG
50    944   GAG CCG GGG TGG GGA AGG ATC ACT GAT TCA CAC CAG  TGG AAC ACC
      989   TTG CTA AGT TTG CAT AAC GCG CAA TTT TAT TTA CTA  CAA CGC ACG

```

- 12 -

1034 CCA GAG GTT GCC CGC AGT CGC GCC ACC CCG TTA TTG GAT TTG ATC  
 1079 AAG ACA GCG TTG ACG CCC CAT CCA CCG CAA AAA CAG GCG TAT GGT  
 5 1124 GTG ACA TTA CCC ACT TCA GTG CTG TTT ATT GCC GGA CAC GAT ACT  
 1169 AAT CTG GCA AAT CTC GGC GGC GCA CTG GAG CTC AAC TGG ACG CTT  
 10 1214 CCA GGT CAG CCG GAT AAC ACG CCG CCA GGT GGT GAA CTG GTG TTT  
 1259 GAA CGC TGG CGT CGG CTA AGC GAT AAC AGC CAG TGG ATT CAG GTT  
 1304 TCG CTG GTC TTC CAG ACT TTA CAG CAG ATG CGT GAT AAA ACG CCG  
 15 1349 CTA TCA TTA AAT ACG CCG CCC GGA GAG GTG AAA CTG ACC CTG GCA  
 1394 GGA TGT GAA GAG CGA AAT GCG CAG GGC ATG TGT TCG TTG GCC GGT  
 20 1439 TTT ACG CAA ATC GTG AAT GAA GCG CGC ATA CCG GCG TGC AGT TTG  
 1484 TAA

One embodiment of the present invention involves the insertion of  
 25 the mutant acid phosphatase/phytase gene into an expression vector system, using  
 recombinant DNA technology well known in the art. This enables one to express  
 this gene in a host cell, allowing for the production and purification of the acid  
 phosphatase/phytase for use in compositions, such as for animal feed.

The DNA of the mutant acid phosphatase/phytase gene can be  
 30 isolated and/or identified using DNA hybridization techniques. Nucleic acid  
 (DNA or RNA) probes of the present invention will hybridize to a complementary  
 nucleic acid under stringent conditions. Less stringent conditions may also be  
 selected. Generally, stringent conditions are selected to be about 50°C lower than  
 the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength  
 35 and pH. The  $T_m$  is the temperature (under defined ionic strength and pH) at which  
 50% of the target sequence hybridizes to a perfectly matched probe. The  $T_m$  is  
 dependent upon the solution conditions and the base composition of the probe,  
 and for DNA:RNA hybridization may be calculated using the following equation:

$$\begin{aligned}
 T_m = 79.8^\circ\text{C} &+ (18.5 \times \text{Log}[\text{Na}^+]) \\
 &+ (58.4^\circ\text{C} \times \%[\text{G}+\text{C}])
 \end{aligned}$$

40

- 13 -

- (820 / #bp in duplex)

- (0.5 x % formamide)

Promega Protocols and Applications Guide, 2d ed., Promega Corp., Madison, WI (1991), which is hereby incorporated by reference. Nonspecific binding may also  
5 be controlled using any one of a number of known techniques such as, for example, blocking the membrane with protein-containing solutions, addition of heterologous RNA, DNA, and SDS to the hybridization buffer, and treatment with RNase.

Generally, suitable stringent conditions for nucleic acid  
10 hybridization assays or gene amplification detection procedures are as set forth above or as identified in Southern, "Detection of Specific Sequences Among DNA Fragments Separated by Gel Electrophoresis," J. Mol. Biol., 98:503-17 (1975), which is hereby incorporated by reference. For example, conditions of hybridization at 42°C with 5X SSPE and 50% formamide with washing at 50°C  
15 with 0.5X SSPE can be used with a nucleic acid probe containing at least 20 bases, preferably at least 25 bases or more preferably at least 30 bases. Stringency may be increased, for example, by washing at 55°C or more preferably 60°C using an appropriately selected wash medium having an increase in sodium concentration (e.g., 1X SSPE, 2X SSPE, 5X SSPE, etc.). If problems remain with  
20 cross-hybridization, further increases in temperature can also be selected, for example, by washing at 65°C, 70°C, 75°C, or 80°C. By adjusting hybridization conditions; it is possible to identify sequences having the desired degree of homology (i.e., greater than 80%, 85%, 90%, or 95%) as determined by the TBLASTN program (Altschul, S.F., et al., "Basic Local Alignment Search Tool,"  
25 J. Mol. Biol. 215:403-410 (1990), which is hereby incorporated by reference) on its default setting.

A preferred method of detecting the mutant acid  
phosphatase/phytase of the present invention is by using the methods known in the art as ligase detection reaction (LDR) and ligase chain reaction (LCR), as  
30 described in Barany, "Genetic Disease Detection and DNA Amplification Using



- 14 -

Cloned Thermostable Ligase," Proc. Natl. Acad. Sci. USA 88(1):189-193 (1991), which is hereby incorporated by reference.

The DNA molecule of the present invention can be expressed in any prokaryotic or eukaryotic expression system by incorporation of the DNA molecule in the expression system in proper orientation and correct reading frame. A variety of host-vector systems may be utilized to express the protein-encoding sequence(s). Preferred vectors include a viral vector, plasmid, cosmid or an oligonucleotide. Primarily, the vector system must be compatible with the host cell used. Host-vector systems include but are not limited to the following:

10 bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA; microorganisms such as yeast containing yeast vectors; mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus); and plant cells infected by bacteria. The expression elements of these vectors vary in their strength and specificities.

15 Depending upon the host-vector system utilized, any one of a number of suitable transcription and translation elements can be used. For example, a DNA molecule in accordance with the present invention is spliced in frame with a transcriptional enhancer element.

Preferred hosts for expressing the DNA molecule of the present invention include fungal cells, including species of yeast or filamentous fungi, may be used as host cells in accordance with the present invention. Preferred yeast host cells include different strains of *Saccharomyces cerevisiae*. Other yeasts like *Kluyveromyces*, *Torulaspora*, and *Schizosaccharomyces* can also be used. In a preferred embodiment, the yeast strain used to overexpress the protein

25 is *Saccharomyces cerevisiae*. Preferred filamentous fungi host cells include *Aspergillus* and *Neurospora*. A more preferred strain of *Aspergillus* is *Aspergillus niger*.

In another preferred embodiment of the present invention, the yeast strain is a methylotrophic yeast strain. Methylotrophic yeast are those yeast

30 genera capable of utilizing methanol as a carbon source for the production of the energy resources necessary to maintain cellular function and containing a gene for

- 15 -

the expression of alcohol oxidase. Typical methylotrophic yeasts include members of the genera *Pichia*, *Hansenula*, *Torulopsis*, *Candida*, and *Karwinskia*. These yeast genera can use methanol as a sole carbon source. In a more preferred embodiment, the methylotrophic yeast strain is *Pichia pastoris*.

5                   Purified protein may be obtained by several methods. The protein or polypeptide of the present invention is preferably produced in purified form (preferably at least about 80%, more preferably 90%, pure) by conventional techniques. Typically, the protein or polypeptide of the present invention is secreted into the growth medium of recombinant host cells. Alternatively, the  
10 protein or polypeptide of the present invention is produced but not secreted into growth medium. In such cases, to isolate the protein, the host cell carrying a recombinant plasmid is propagated, lysed by sonication, heat, or chemical treatment, and the homogenate is centrifuged to remove cell debris. The supernatant is then subjected to sequential ammonium sulfate precipitation. The  
15 fraction containing the polypeptide or protein of the present invention is subjected to gel filtration in an appropriately sized dextran or polyacrylamide column to separate the proteins. If necessary, the protein fraction may be further purified by HPLC.

                  The present invention also provides a yeast strain having a  
20 heterologous gene which encodes a protein or polypeptide with phytase activity. The heterologous gene should be functionally linked to a promoter capable of expressing phytase in yeast.

                  Yet another aspect of the invention is a vector for expressing phytase in yeast. The vector carries a gene from a non-yeast organism which  
25 encodes a protein or polypeptide with phytase activity. The phytase gene can be cloned into any vector which replicates autonomously or integrates into the genome of yeast. The copy number of autonomously replicating plasmids, e.g. YEp plasmids, may be high, but their mitotic stability may be insufficient (Bitter et al., "Expression and Secretion Vectors for Yeast," Meth. Enzymol. 153:516-44  
30 (1987), which is hereby incorporated by reference). They may contain the 2 mu-plasmid sequence responsible for autonomous replication, and an *E. coli*

- 16 -

sequence responsible for replication in *E. coli*. The vectors preferably contain a genetic marker for selection of yeast transformants, and an antibiotic resistance gene for selection in *E. coli*. The episomal vectors containing the ARS and CEN sequences occur as a single copy per cell, and they are more stable than the YEp  
5 vectors. Integrative vectors are used when a DNA fragment is integrated as one or multiple copies into the yeast genome. In this case, the recombinant DNA is stable and no selection is needed (Struhl et al., "High-Frequency Transformation of Yeast: Autonomous Replication of Hybrid DNA Molecules," Proc. Nat'l Acad. Sci. USA 76:1035-39 (1979); Powels et al., Cloning Vectors, I-IV, et seq.  
10 Elsevier, (1985); and Sakai et al., "Enhanced Secretion of Human Nerve Growth Factor from *Saccharomyces Cerevisiae* Using an Advanced  $\delta$ -Integration System," Biotechnology 9:1382-85 (1991), which are hereby incorporated by reference). Some vectors have an origin of replication, which functions in the selected host cell. Suitable origins of replication include 2 $\mu$ , ARS1, and 25 $\mu$ M.  
15 The vectors have restriction endonuclease sites for insertion of the fusion gene and promoter sequences, and selection markers. The vectors may be modified by removal or addition of restriction sites, or removal of other unwanted nucleotides.

The phytase gene can be placed under the control of any promoter (Stetler et al., "Secretion of Active, Full- and Half-Length Human Secretory  
20 Leukocyte Protease Inhibitor by *Saccharomyces cerevisiae*," Biotechnology 7:55-60, (1989), which is hereby incorporated by reference). One can choose a constitutive or regulated yeast promoter. Suitable promoter sequences for yeast vectors include, among others, promoters for metallothionein, 3-phosphoglycerate kinase (Hitzeman et al., J. Biol. Chem. 255:2073 (1980), which is hereby  
25 incorporated by reference) or other glycolytic enzymes (Hess et al., J. Adv. Enzyme Reg. 7:149 (1968); and Holland et al., Biochem. 17:4900, (1978), which are hereby incorporated by reference), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase,  
30 pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. Other suitable vectors and promoters for use in yeast expression are further described in EP A-73,657 to Hitzeman, which is hereby incorporated by

- 17 -

reference. Another alternative is the glucose-repressible ADH2 promoter described by Russell et al., J. Biol. Chem. 258:2674 (1982) and Beier et al., Nature 300:724 (1982), which are hereby incorporated by reference.

One can choose a constitutive or regulated yeast promoter. The strong promoters of e.g., phosphoglycerate kinase (PGK) gene, other genes encoding glycolytic enzymes, and the alpha -factor gene, are constitutive. When a constitutive promoter is used, the product is synthesized during cell growth. The ADH2 promoter is regulated with ethanol and glucose, the GAL-1-10 and GAL7 promoters with galactose and glucose, the PHO5 promoter with phosphate, and the metallothionine promoter with copper. The heat shock promoters, to which the HSP150 promoter belongs, are regulated by temperature. Hybrid promoters can also be used. A regulated promoter is used when continuous expression of the desired product is harmful for the host cells. Instead of yeast promoters, a strong prokaryotic promoter such as the T7 promoter, can be used, but in this case the yeast strain has to be transformed with a gene encoding the respective polymerase. For transcription termination, the HSP150 terminator, or any other functional terminator is used. Here, promoters and terminators are called control elements. The present invention is not restricted to any specific vector, promoter, or terminator.

The vector may also carry a selectable marker. Selectable markers are often antibiotic resistance genes or genes capable of complementing strains of yeast having well characterized metabolic deficiencies, such as tryptophan or histidine deficient mutants. Preferred selectable markers include URA3, LEU2, HIS3, TRP1, HIS4, ARG4, or antibiotic resistance genes.

The vector may also have an origin of replication capable of replication in a bacterial cell. Manipulation of vectors is more efficient in bacterial strains. Preferred bacterial origin of replications are ColE1, Ori, or oriT.

Preferably, the protein or polypeptide with phytase activity is secreted by the cell into growth media. This allows for higher expression levels and easier isolation of the product. The protein or polypeptide with phytase

- 18 -

activity is coupled to a signal sequence capable of directing the protein out of the cell. Preferably, the signal sequence is cleaved from the protein.

A leader sequence either from the yeast or from phytase genes or other sources can be used to support the secretion of expressed phytase enzyme  
5 into the medium. The present invention is not restricted to any specific type of leader sequence or signal peptide.

Suitable leader sequences include the yeast alpha factor leader sequence, which may be employed to direct secretion of the phytase. The alpha factor leader sequence is often inserted between the promoter sequence and the  
10 structural gene sequence (Kurjan et al., Cell 30:933, (1982); Bitter et al., Proc. Natl. Acad. Sci. USA 81:5330, (1984); U.S. Patent No. 4,546,082; and European published patent application No. 324,274, which are hereby incorporated by reference). Another suitable leader sequence is the *S. cerevisiae* MF alpha 1 (alpha-factor) is synthesized as a prepro form of 165 amino acids comprising  
15 signal-or prepeptide of 19 amino acids followed by a "leader" or propeptide of 64 amino acids, encompassing three N-linked glycosylation sites followed by (LysArg(Asp/Glu, Ala)<sub>2-3</sub> alpha-factor)<sub>4</sub> (Kurjan, et al., Cell 30:933-43 (1982), which is hereby incorporated by reference). The signal-leader part of the preproMF alpha 1 has been widely employed to obtain synthesis and secretion of  
20 heterologous proteins in *S. cerevisiae*. Use of signal/leader peptides homologous to yeast is known from: U.S. Patent No. 4,546,082; European Patent Applications Nos. 116,201, 123,294, 123,544, 163,529, and 123,289; and DK Patent Application No. 3614/83, which are hereby incorporated by reference. In European Patent Application No. 123,289, which is hereby incorporated by  
25 reference, utilization of the *S. cerevisiae* a-factor precursor is described whereas WO 84/01153, which is hereby incorporated by reference, indicates utilization of the *Saccharomyces cerevisiae* invertase signal peptide, and German Patent Application DK 3614/83, which is hereby incorporated by reference, indicates utilization of the *Saccharomyces cerevisiae* PH05 signal peptide for secretion of  
30 foreign proteins.

- 19 -

The alpha -factor signal-leader from *Saccharomyces cerevisiae* (MF alpha 1 or MF alpha 2) may also be utilized in the secretion process of expressed heterologous proteins in yeast (U.S. Patent No. 4,546,082; European Patent Applications Nos. 16,201, 123,294, 123,544, and 163,529, which are  
5 hereby incorporated by reference). By fusing a DNA sequence encoding the *S. cerevisiae* MF alpha 1 signal/ leader sequence at the 5' end of the gene for the desired protein, secretion and processing of the desired protein was demonstrated. The use of the mouse salivary amylase signal peptide (or a mutant thereof) to provide secretion of heterologous proteins expressed in yeast has been described  
10 in Published PCT Applications Nos. WO 89/02463 and WO 90/10075, which are hereby incorporated by reference.

U.S. Patent No. 5,726,038 describes the use of the signal peptide of the yeast aspartic protease 3, which is capable of providing improved secretion of proteins expressed in yeast. Other leader sequences suitable for facilitating  
15 secretion of recombinant polypeptides from yeast hosts are known to those of skill in the art. A leader sequence may be modified near its 3' end to contain one or more restriction sites. This will facilitate fusion of the leader sequence to the structural gene.

Yeast transformation protocols are known to those of skill in the  
20 art. One such protocol is described by Hinnen et al., Proc. Natl. Acad. Sci. USA 75:1929 (1978), which is hereby incorporated by reference. The Hinnen et al. protocol selects for Trp transformants in a selective medium, wherein the selective medium consists of 0.67% yeast nitrogen base, 0.5% casamino acids, 2% glucose, 10 µg/ml adenine and 20 µg/ml uracil.

25 The gene may be maintained in a stable expression vector, an artificial chromosome, or by integration into the yeast host cell chromosome. Integration into the chromosome may be accomplished by cloning the phytase gene into a vector which will recombine into a yeast chromosome. Suitable vectors may include nucleotide sequences which are homologous to nucleotide  
30 sequences in the yeast chromosome. Alternatively, the phytase gene may be



- 20 -

located between recombination sites, such as transposable elements, which can mobilize the gene into the chromosome.

Another aspect of the present invention relates to improving the enzymatic properties of a wild-type acid phosphatase/phytase. This is desirably achieved by altering the amino acid sequence of the wild-type acid phosphatase/phytase at positions 200, 207, and 211 as described above. For example, these modifications cause the acid phosphatase/phytase to have improved thermostability. Alternatively, the improved enzymatic property is phytase activity at a pH range of between about pH 3.5 to about pH 5.5.

While the phytase enzyme produced in a yeast system released phytate-P from corn and soy as effectively as the currently commercial phytase, it appeared to be more thermostable. This phytase overexpression system in yeast can be used to provide thermostable phytase for use in the food and feed industries.

The improved acid phosphatase/phytase of this invention can be used in animal feed to improve the digestion of phosphate by such simple-stomached animals as poultry, swine, pre-ruminant calves, zoo animals, and pets (e.g., cats and dogs). The present invention would decrease the need for supplementing animal feed with large amounts of inorganic phosphate, resulting in a less expensive form of animal feed and one that is less concentrated with the non-renewable form of phosphate. Since the present invention enhances the ability of simple-stomached animals to absorb phosphate, the fecal waste of these animals will contain less unutilized phytate-phosphate, which decreases the amount of phosphate pollution.

In making the animal feed composition of the present invention, the mutant acid phosphatase/phytase is combined with a raw plant material and then processed into a pellet or powder form. The raw plant material may include various combinations of a number of plants and/or plant by-products commonly used in animal feed, including plants such as maize, soybean, wheat, rice, cotton seed, rapeseed, sorghum, and potato. In addition, the animal feed composition

- 21 -

may be fortified with various vitamins, minerals, animal protein, and antibiotics. One embodiment of the animal feed composition includes a mixture of appropriate concentrations of the mutant acid phosphatase/phytase, an energy source(s) (e.g., maize, wheat), a protein source(s) (e.g., soybean, rice, cottonseed meal, rapeseed meal, sorghum meal), and vitamin/mineral supplements. In particular, the amount of the mutant acid phosphatase/phytase would be 300-1,000 Units/kg of feed. One example of a typical animal feed composition would include 50-70% maize, 20-30% soybean, approximately 1% vitamin and mineral supplements, and an appropriate amount of mutant acid phosphatase/phytase.

10 In addition, the mutant acid phosphatase/phytase of the present invention could be used to enhance human nutrition, particularly by increasing the uptake of such minerals as zinc and iron. By adding the mutant acid phosphatase/phytase to the diets of humans, various problems arising from nutrient deficiencies, such as stunted growth and mental retardation in children, 15 could be treated and avoided.

The invention also provides a basic molecular method that can be broadly applied to design mutant acid phosphatases/phytases derived from various source organisms, resulting in mutants with enhanced enzymatic properties such as greater thermostability and catalytic efficiency. This method includes 20 identifying and isolating a gene of a wild-type enzyme and using this gene as the object of site-directed mutagenesis in order to enhance the enzyme's function and/or stability. One aspect of this invention is to use site-directed mutagenesis to make targeted mutations to the wild-type gene in order to add N-glycosylation sites to the wild-type enzyme and/or to alter the enzyme's physiochemical 25 properties (e.g., increasing the net positive charge of the enzyme). In addition, targeted mutations can be made to the wild-type gene in order to eliminate certain disulfide bonds found in the final protein product, resulting in enhanced thermostability and catalytic function.

## EXAMPLES

### Example 1 - Sequence Analysis for Designing Mutations

The criteria for designing mutations to enhance glycosylation of the AppA enzyme were 1) the potential glycosylation site should have 25% or greater solvent accessibility, and 2) the site should be easily engineered by a single residue change to give an N-linked glycosylation motif (Asn-X-Ser or Asn-X-Thr, where X is not a proline). Initially, in the absence of a crystal structure for the AppA enzyme, the crystal structure of rat acid phosphatase (35% sequence identity) (Schneider, G. et al., EMBO J. 12:2609-15 (1993), which is hereby incorporated by reference) was used to calculate accessibilities as follows. First, the AppA enzyme and rat acid phosphatase were aligned to several closely related phosphatases/phytases using the multi-sequence alignment program PIMA (Smith, R. et al., Protein Engineering 5:35-41 (1992), which is hereby incorporated by reference). The aligned sequences included: human prostatic acid phosphatase precursor (GeneBank Accession No. P15309); *Caenorhabditis elegans* histidine acid phosphatase (GeneBank Accession No. Z68011); *Aspergillus fumigatus* phytase (GeneBank Accession No. U59804); *Pichia angusta* repressible acid phosphatase (GeneBank Accession No. AF0511611); rat acid phosphatase (GeneBank Accession No. 576257), and *E. coli appA* (GeneBank Accession No. M58708). Next, the solvent accessible surface of all of the amino acids of rat phosphatase was determined using the program DSSP (definition of secondary structure of proteins) (Kabsch, W. et al., Biopolymers 22:2577-637 (1983), which is hereby incorporated by reference), converting these values to percent accessibility by dividing the total surface area of the corresponding amino acid as it has been previously described (Eisenberg, D. et al., Chemica Scripta 29A, 217-221 (1989), which is hereby incorporated by reference). Only residues greater than 25% solvent were considered accessible. Values were assigned to the corresponding amino acids in the AppA enzyme based on the sequence alignment described above, under the assumption that the overall structure of rat acid phosphatase and the AppA enzyme would be conserved. Finally, the putative solvent accessible residues were examined to determine which could be easily

converted to an N-glycosylation site by point mutation. Out of 31 potential sites, 5 were selected that best fit the desired criteria. An additional mutation C200N was incorporated using primer P2 designed for another *appA* mutagenesis study. From the alignment performed, the mutation C200N is in a gapped region and  
5 C200 is involved with C210 (labeled as C178/C188 by Lim et al., Nat. Struct. Biol. 7:108-13 (2000), which is hereby incorporated by reference) in forming a unique disulfide bond between helix G and the GH loop (an unorganized configuration between the G and H helices) in the  $\alpha$ -domain of the protein (Lim et al., Nat. Struct. Biol. 7:108-13 (2000), which is hereby incorporated by reference).  
10 Correspondingly, 6 PCR primers were designed: E2 and K2 for amplifying the wild-type sequence of *appA* (Dassa, J. et al., J. Bacteriol. 172:5497-500 (1990), which is hereby incorporated by reference) and the others for developing four mutants (Table 1 and Figure 1). All the primers were synthesized by the Cornell University Oligonucleotide Synthesis Facility (Ithaca, NY).

**TABLE 1****Modified primers and index of surface solvent accessibility for mutations**

Primer <sup>1</sup>	Position <sup>2</sup>	Primer sequence <sup>3</sup>	Modification <sup>4</sup>	Accessibility <sup>5</sup> (%)
E2 (f)	241-264	5' GGAATTCGCTCAGAGCCGGA 3' (SEQ. ID. No. 5)	<i>EcoRI</i> restriction site	-----
A1 (r)	565-592	5' CTGGGTATGGTTGGTTATATTACAG TCAGGT 3' (SEQ. ID. No. 6)	A131N	1.05
			V134N	0.55
P2 (f)	772-795	5' CAAACTTGAACTTAAACGTGAG 3' (SEQ. ID. No. 7)	C200N	nd
P3 (r)	796-825	5' CCTGCGTTAAGTTACAGCTTTCATT CTGTTT 3' (SEQ. ID. No. 8)	D207N	0.63
			S211N	0.65
K2 (r)	1469-1491	5' GGGGTACCTTACAACTGCACG 3' (SEQ. ID. No. 9)	<i>KpnI</i> restriction site	-----

<sup>1</sup>: f, forward; r, reverse.

<sup>2</sup>: Nucleotide position based on the *E. coli* periplasmic pH 2.5 acid phosphatase (GeneBank Accession No. M58708).

<sup>3</sup>: Underlined nucleotides were substituted.

<sup>4</sup>: Amino-acid mutation or restriction site added. The coding region starts at the codon 20 and ends at the codon 432. Amino acids A131, V134, C200, D207, and S211 are labeled A109, V112, C178, D185, and S189 by Lim et al. (Lim et al., *Nat. Struct. Biol.* 7:108-13 (2000), which is hereby incorporated by reference).

<sup>5</sup>: Percentage of amino acid surface solvent accessibility (Smith, R. et al., *Protein Engineering* 5:35-41 (1992); Kabsch, W. et al., *Biopolymers* 22:2577-637 (1983), which are hereby incorporated by reference); nd, not determined.

## 5 **Example 2 - Construction of Mutants by PCR**

The *E. coli appA* mutants were constructed using the megaprimer site-directed mutagenesis method adapted from previous studies (Seraphin, B. et al., *Nucl. Acids Res.* 24:3276-77 (1996); Smith, A.M. et al., *BioTechniques* 22:438-39 (1997), which are hereby incorporated by reference). To amplify the intact coding region of *appA*, the PCR was set up in a 50 µl final volume containing 200 ng DNA of *appA* inserted in a pAPPA1 plasmid isolated from

- 25 -

*E. coli* strain BL21 (Dassa, J. et al., *J. Bacteriol.* 172:5497-500 (1990), which is hereby incorporated by reference), 50 pmol of each primer E2 and K2, 5 U of AmpliTaq DNA polymerase (Perkin Elmer, Norwalk, CT), 10 mM Tris-HCl pH 8.3, 50 mM KCl, 12.5 mM MgCl<sub>2</sub>, and 200 mM each dNTPs (Promega Corp., Madison, WI). The reaction was performed using the GeneAmp PCR system 2400 (Perkin Elmer), and included 1 cycle at 94°C (3 min), 30 cycles of [94°C (0.5 min), 54°C (1 min) and 72°C (1.5 min) ] and 1 cycle at 72°C (10 min). Megaprimers for mutants were produced in a separated round of PCR (Table 2).

10 **TABLE 2*****E. coli appA* mutant denomination and construction**

		Construct <sup>1</sup>	Size bp	No. glycosylation
Mutants	R	E2A1P3K2	1350	7
	U	E2P2P3K2	1350	5
	Y	E2A1P2P3K2	1350	7
Wild type	r-AppA	E2K2	1350	3

<sup>1</sup> See Table 1 for primer denomination.

The first mutagenic PCR reaction (100 µl) was performed as described above, using 4 µl of the intact *appA* PCR reaction mixture and the respective modified primers listed in Table 1. All megaprimer PCR products were resolved in a 1.5% low melting agarose (Gibco BRL, Grand Island, NY) gel electrophoresis. The expected fragments were excised and eluted with GENECLEAN II kit (Bio101, Vista, CA). The final mutagenic PCR reaction (100 µl) was set up as described above, using 4 µl of the *appA* PCR product and varying concentrations of the purified megaprimer (50 ng to 4 µg), depending on its size. Five thermal cycles were set up at 94°C for 1 min and 70°C for 2 min. While at 70°C, 1 µmol of forward primer and 2 U of AmpliTaq DNA polymerase



- 26 -

were added and gently mixed with the reaction, and thermal cycling continued for 25 times at 94°C for 1 min, 56°C for 1 min and 70°C for 1.5 min.

### **Example 3 - Subcloning and Expression**

5                    *E. coli* strain TOP10F' (Invitrogen, San Diego, CA) was used as an initial host. The PCR fragments were purified and cloned into pGEMT-Easy vector (Promega) according to the manufacturer's instructions. *EcoRI* digestion of the isolated plasmid DNA was used to screen for positive transformants. The resulting inserts were cloned into pPICZαA (Kit Easy-Select, Invitrogen) at the  
10 *EcoRI* site and transformed into TOP10F' cells plated on LB (Luria-Bertani) medium containing 25 µg/ml Zeocin. Colonies with desired inserts in the correct orientations were selected using *SalI* or *BstXI* restriction digestions of plasmid DNA. *P. pastoris* strain X33 (Mut+ His+) was used as the host for protein expression (Invitrogen) and grown in YPD (yeast extract peptone dextrose  
15 medium) liquid medium prior to electroporation. Two µg of plasmid DNA were linearized using restriction enzyme *BglII* or *PmeI* and then transformed into X33 according to the manufacturer's instructions (Invitrogen). After selected transformants were incubated in minimal media with glycerol (GMGY) for 24h, 0.5% methanol medium (GMMY) was used to induce protein expression.

20

### **Example 4 - Enzyme Purification and Biochemical Characterization**

The expressed r-AppA and mutant enzymes in the medium supernatant were subjected to a two-step ammonium sulfate precipitation (25% and 75%) as previously described (Rodriguez, E. et al., Biochem. Biophys. Res. Commun. 257:117-23 (1999), which is hereby incorporated by reference). The  
25 suspension of the first round was centrifuged at 4°C, 25,000 x g for 20 min. The pellet of the second round was suspended in 10 ml and dialyzed overnight against 25 mM Tris-HCl, pH 7. After dialysis, the protein extract was loaded onto a DEAE (diethylaminoethyl)-Sepharose column (Sigma, St. Louis, MO)  
30 equilibrated with 25 mM Tris-HCl, pH 7. The bound protein was eluted with 1 M NaCl in 25 mM Tris-HCl, pH 7. Those three fractions exhibiting the highest activities were pooled and dialyzed against 25 mM Tris-HCl, pH 7.5 for the

- 27 -

following analysis. Phytase activity was measured using sodium phytate as the substrate (Rodriguez, E. et al., Biochem. Biophys. Res. Commun. 257:117-23 (1999); Piddington, C.S. et al., Gene 133:55-62 (1993), which are hereby incorporated by reference). The enzyme was diluted in 0.25 M glycine-HCl, pH 2.5, and an equal volume of substrate solution containing 11 mM sodium phytate (Sigma) was added. After incubation of the sample for 15 min at 37°C, the reaction was stopped by addition of an equal volume of 15% trichloroacetic acid. Free inorganic phosphorus was measured at 820 nm after 0.2 ml of the sample was mixed with 1.8 ml of H<sub>2</sub>O and 2 ml of a solution containing 0.6 M H<sub>2</sub>SO<sub>4</sub>, 2% ascorbic acid, and 0.5% ammonium molybdate, followed by incubation for 20 min at 50°C. One phytase unit was defined as the amount of activity that releases 1 µmol of inorganic phosphorus from sodium phytate per minute at 37°C. The final concentrations of sodium phytate used for the enzyme kinetics were: 0.1, 0.25, 0.5, 0.75, 1, 2.5, 10, and 25 mM. Acid phosphatase activity was assayed using pNPP (Sigma) at a final concentration of 25 mM (Smith, R. et al., Protein Engineering 5:35-41 (1992), which is hereby incorporated by reference). To 50 µl of enzyme (40 nmol), 850 µl of 250 mM glycine-HCl, pH 2.5, were added. After 5 min of incubation at 37°C, 100 µl of pNPP was added. The released *p*-nitrophenol was measured at 405 nm after 0.1 ml of the sample was mixed with 0.9 ml of 1 M NaOH and incubated for 10 min. The final concentrations of pNPP used for the enzyme kinetics were: 0.1, 0.2, 0.75, 1, 2.5, 10, and 25 mM. One unit of acid phosphatase/phytase activity was defined as the amount of enzyme catalyzing the formation of 1 µmol of *p*-nitrophenol per minute. Before the thermostability assay, the enzyme (2 mg/ml) was diluted 1:400 in 0.2 M glycine-HCl, pH 2.5. The diluted samples were incubated for 15 min at 25, 55, 80, and 90°C. After the samples were cooled on ice for 30 min, their remaining phytase activities were measured as described above. Deglycosylation of purified enzymes was done by incubating 100 µg of total protein with 0.5 IU endoglycosidase H<sub>f</sub> (Endo H<sub>f</sub>) for 4 h at 37°C according to the manufacturer's instructions (New England Biolabs, Beverly, MA). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), 15% (w/v) gel was performed as previously described (Laemmli, U.K., Nature 227:680-85 (1970), which is hereby

- 28 -

incorporated by reference). Protein concentrations were determined using the Lowry method (Lowry, O.H. et al., J. Biol. Chem. 193:265-75 (1951), which is hereby incorporated by reference).

5 Data were analyzed using SAS (release 6.04, SAS institute, Cary, NC, USA).

**Example 5 - Effects of Site-Directed Mutagenesis on Phytase Expression and Glycosylation**

10 Genomic DNA from each yeast transformant was extracted to amplify the desired mutated *appA* by PCR (polymerase chain reaction) using E2 and K2 primers. All the desired mutations were confirmed by sequencing. For each mutant, 24 colonies were analyzed for phytase activity at various times after  
15 induction. All of the three mutants, Mutant R, Mutant U, and Mutant Y, along with r-AppA, were expressed and secreted, resulting in a time-dependent accumulation of extracellular phytase activity that reached plateau at 96 h after methanol induction. The plateau activity in the medium supernatant was 35, 175, 57, and 117 U/mL, respectively (Table 3). Yeast X33 transformed with the  
20 expression vector pPICZ $\alpha$ A was used as a control and did not give any activity or phytase protein in SDS-PAGE. On the purified protein basis, Mutant U had the highest specific phytase activity, 63 U/mg, followed by Mutant Y, r-AppA and  
• Mutant R (51, 41 and 32 U/mg protein, respectively). The protein yield recovered after purification was 654, 324, 688 and 425 mg/L for the Mutants U and Y, r-  
25 AppA and Mutant R, respectively (Table 3).

- 29 -

**TABLE 3****Phytase yield and specific activity of r-AppA and the three mutants**

Protein	Phytase activity <sup>1</sup>	Protein yield <sup>2</sup>	Specific activity <sup>3</sup>	
			-Endo H <sub>f</sub>	+Endo H <sub>f</sub>
r-AppA	117 ± 15	688 ± 44	41 ± 3	37 ± 4
R	35 ± 4	425 ± 26	32 ± 2	29 ± 2
U	175 ± 19	654 ± 39	63 ± 4*	65 ± 5*
Y	57 ± 8	324 ± 18	51 ± 5	46 ± 6

<sup>1</sup>: Phytase activity (U/ml) in GMMY media after 96 h of culture.<sup>2</sup>: Protein yield (milligrams of purified protein per liter of culture).<sup>3</sup>: Specific phytase activity (units per milligram of purified protein).\* Indicates significant difference ( $P < 0.05$ ) versus the r-AppA control. Results are representative of three experiments.

In SDS-PAGE, the band size of the purified r-AppA was 50-56 kDa, while that of Mutant R was 68-70 kDa and that of Mutant Y was 86-90 kDa (Figure 2). This gave an enhancement of the glycosylation level from 14% in r-AppA to 48% in Mutant R and 89% in Mutant Y. The level of glycosylation in Mutant U appeared equivalent to that of r-AppA. All of these recombinant enzymes showed similar molecular mass, 45 to 48 kDa, after deglycosylation by Endo H<sub>f</sub>. Deglycosylation did not significantly affect the specific activity for all the mutants or r-AppA (Table 3). However, treating these purified proteins with both  $\beta$ -mercaptoethanol and Endo H<sub>f</sub> caused a complete loss of phytase activity.

- 30 -

**Example 6 - Effects of Site-Directed Mutagenesis on Phytase pH and Temperature Optima and Thermostability**

Although Mutants R, U, and Y shared the same pH optimum (2.5) with that of r-AppA, Mutant U was more ( $p < 0.05$ ), while Mutant Y was less ( $p < 0.05$ ), active than r-AppA at the pH 3.5, 4.5, and 5.5 (Figure 3). The temperature optimum was 65°C for Mutant U and 55°C for the other two mutants and r-AppA. In 0.2 M glycine-HCl, pH 2.5, Mutant U exhibited a higher ( $p < 0.05$ ) residual phytase activity than that of r-AppA after being heated at 80 and 90°C for 15 min (Figure 4).

**Example 7 - Effects of Site-Directed Mutagenesis on Enzyme Kinetics**

The  $K_m$  value for pNPP (*p*-nitrophenyl phosphate) was reduced by one-half and the one for sodium phytate by 70% with Mutant U, versus r-AppA ( $P < 0.05$ ) (Table 4). Consequently, Mutant U demonstrated a 1.9-fold increase in its apparent catalytic efficiency  $k_{cat}/K_m$  for pNPP and a 5.2-fold increase for sodium phytate than that of r-AppA. Although the  $k_{cat}/K_m$  values for Mutant Y were also significantly different from those of r-AppA for sodium phytate, the actual enhancement was relatively small. In contrast, Mutant R demonstrated a significantly lower catalytic efficiency than that of r-AppA for both substrates.

**TABLE 4**  
**Catalytic properties of r-AppA and the three mutants<sup>1</sup>**

Enzyme	Substrate					
	pNPP			Na-Phytate		
	$K_m$ (mM)	$k_{cat}$ (min <sup>-1</sup> )	$k_{cat}/K_m$ (min <sup>-1</sup> M <sup>-1</sup> )	$K_m$ (mM)	$k_{cat}$ (min <sup>-1</sup> )	$k_{cat}/K_m$ (min <sup>-1</sup> M <sup>-1</sup> )
r-AppA	3.66 ± 0.44	752 ± 7.9	(2.0 ± 0.18) × 10 <sup>5</sup>	1.95 ± 0.25	2148 ± 33	(1.11 ± 0.13) × 10 <sup>6</sup>
R	7.87 ± 0.84*	390 ± 5.9*	(0.5 ± 0.07) × 10 <sup>5</sup> *	3.07 ± 0.26*	1657 ± 23*	(0.54 ± 0.09) × 10 <sup>6</sup> *
U	1.86 ± 35*	1073 ± 13*	(5.8 ± 0.37) × 10 <sup>5</sup> *	0.58 ± 0.08*	4003 ± 56*	(6.90 ± 0.70) × 10 <sup>6</sup> *
Y	3.18 ± 0.39	787 ± 6.7	(2.5 ± 0.17) × 10 <sup>5</sup>	2.03 ± 0.19	3431 ± 41*	(1.69 ± 0.21) × 10 <sup>6</sup> *

<sup>1</sup> Reaction velocity measurements were performed in triplicate as described herein. The values of  $K_m$  were calculated using the Lineweaver-Burk plot method. All reactions were measured in 0.25 M glycine-HCl, pH 2.5.

\* Indicates significant difference ( $P < 0.05$ ) versus the r-AppA control. Results are representative of five independent experiments.

The above results indicate that additional N-glycosylation sites and/or other amino acid changes can be added to the AppA enzyme by site-directed mutagenesis. Compared with the r-AppA produced by the intact *appa* gene, the mutant enzymes R and Y clearly demonstrated enhanced glycosylation, as shown by their differences in molecular masses before and after deglycosylation. Thus, the engineered N-glycosylation sites in these two mutants were indeed recognized by *P. pastoris* and processed correctly. Because of the multiple mutations in Mutants R and Y, these results cannot assess the level of glycosylation at specific engineered sites, but useful information can be derived by comparisons between the mutants and r-AppA. First, although both Mutants R and Y had four additional N-glycosylation sites with respect to r-AppA, Mutant Y displayed greater than 40% more N-glycosylation than R (89% vs 48%). Because the substitution C200N in Mutant Y was the only difference between these two variants and that mutation added no additional putative N-glycosylation site, it



seems that changing C200N itself might enhance N-glycosylation at certain sites. Second, although Mutant U had two additional N-glycosylation sites (Asn 207 and Asn 211), its apparent molecular weight was the same as r-AppA, suggesting the two engineered glycosylation sites in Mutant U were silent. This demonstrates  
5 that although the presence of such a signal sequence is required for glycosylation, it does not necessarily result in glycosylation (Meldgaard, M. et al., Microbiol. 140:159-66 (1994), which is hereby incorporated by reference). Possibly, the residues mutated in the case of Mutant U were not as solvent accessible as the structure-based sequence alignment would lead one to believe. The recently  
10 published crystal structure of the AppA enzyme may help answer this question (Lim et al., Nat. Struct. Biol. 7:108-13 (2000); Jia, Z. et al., Acta Crystallogr. D Biol. Crystallogr. 54:647-49 (1998), which are hereby incorporated by reference). Lastly, Mutant R had a significant increase in glycosylation compared with that of Mutant U. The difference might be caused by the two added N-glycosylation sites  
15 at A131N and V134N in Mutant R. Given the above results, the following observations can be made: 1) the substitutions A131N and V134N result in increased glycosylation of the AppA enzyme; 2) the substitutions D207N and S211N were silent; 3) the substitution C200N appeared to enhance glycosylation at other sites in the case of Mutant Y, but not in Mutant U.

20 In general, additional glycosylation of proteins has been shown to facilitate folding and increase stability (Haraguchi, M. et al., Biochem. J. 312:273-80 (1995); Imperiali, B. et al., Proc. Natl. Acad. Sci. USA. 92:97-112 (1995), which are hereby incorporated by reference). Contrary to expectations, Mutants R and Y did not demonstrate enhanced thermostability, despite elevated levels of  
25 glycosylation. Surprisingly, Mutant U displayed a greater thermostability despite having the same level of glycosylation as r-AppA. Although performing C200N does not mean that N-glycosylation at other sites has occurred, greater glycosylation at specific sites is feasible. Seemingly, the mutations *per se* rather than glycosylation had contributed to this effect. A recent study described the  
30 production of six different phytases expressed in either *Aspergillus niger* or the yeast *Hansenula polymorpha* (Wyss, M. et al., Appl. Environ. Microbiol. 65:359-66 (1999), which is hereby incorporated by reference). The results indicated that

levels of glycosylation depended on the host chosen, but had no significant effect on thermostability, specific activity or protein refolding (Wyss, M. et al., Appl. Environ. Microbiol. 65:359-66 (1999), which is hereby incorporated by reference).

5                   The kinetic data indicate that all the three mutants and r-AppA had lower  $K_m$  and higher  $k_{cat}/K_m$  for sodium phytate than for pNPP. Clearly, these recombinant enzymes have higher apparent efficiency for the former than the latter, demonstrating that the AppA enzyme is more a phytase than acid phosphatase (Lim et al., Nat. Struct. Biol. 7:108-13 (2000); Rodriguez, E. et al.,  
10 Biochem. Biophys. Res. Commun. 257:117-23 (1999), which are hereby incorporated by reference). Mutant U exhibited the largest enhancement in its apparent efficiency for both substrates over that of r-AppA. The enhancement in  $k_{cat}/K_m$  is most likely due to a large decrease in  $K_m$  (1.86 vs 3.66 mM for pNPP and 0.58 vs 1.95 mM for sodium phytate). This means that the Mutant U is  
15 saturated at a much lower concentration of substrate than r-AppA. In addition, there was also a significant difference in  $k_{cat}$  for both substrates between these two forms of phytase. Based on the structure of rat acid phosphatase (Schneider, G. et al., EMBO J. 12:2609-15 (1993), which is hereby incorporated by reference), these mutations do not seem to be involved in the enzyme active site or the  
20 formation of acid phosphatase dimer. Probably, these mutations singly or jointly affect the conformational flexibility of the enzyme, such as described previously for another protein (Kern, G. et al., Protein Sci. 2:1862-68 (1993), which is hereby incorporated by reference). Based on the recently solved crystal structures of *E. coli* phytase (Lim et al., Nat. Struct. Biol. 7:108-13 (2000); Jia, Z. et al., Acta  
25 Crystallogr. D Biol. Crystallogr. 54:647-49 (1998), which are hereby incorporated by reference), none of these mutations are directly involved in the substrate-binding pocket. However, C200 and C210, labeled as C178 and C188 by Lim et al. (Lim et al., Nat. Struct. Biol. 7:108-13 (2000), which is hereby incorporated by reference), are involved in a disulfide bond between helix G and the GH loop in  
30 the  $\alpha$ -domain of the protein (Lim et al., Nat. Struct. Biol. 7:108-13 (2000), which is hereby incorporated by reference). With the mutation C200N, the unique disulfide bond into the  $\alpha$ -domain is no longer present in the GH loop. This

- 34 -

change may result in a better flexibility of the  $\alpha$ -domain toward the central cavity or "substrate-binding site" of the enzyme (Lim et al., Nat. Struct. Biol. 7:108-13 (2000), which is hereby incorporated by reference). This internal flexibility may be also supported by the fact that Mutant U, and to a lesser extent Mutant Y, demonstrated improvement in the catalytic efficiency for sodium phytate hydrolysis. Since there was no enhanced glycosylation for Mutant U, engineered glycosylation sites N207 and N211, labeled as D185 and S189 by Lim et al. (Lim et al., Nat. Struct. Biol. 7:108-13 (2000), which is hereby incorporated by reference), may be masked from the exposed surface. The improvement of thermostability for Mutant U may be therefore explained by an increasing number of hydrophobic interactions not presented in Mutant Y or Mutant R.

It is worth mentioning that the specific activities of phytase in all the three mutants and r-AppA were not significantly affected by deglycosylation. However, deglycosylation, as shown in glycoprotein hormones (Terashima, M. et al., Eur. J. Biochem. 226:249-54 (1994), which is hereby incorporated by reference) or the *Schwanniomyces occidentalis*  $\alpha$ -amylase expressed in *S. cerevisiae* (Han, Y. et al., Appl. Environ. Microbiol. 65:1915-18 (1999), which is hereby incorporated by reference), may be associated with possible conformational changes that modulate the substrate binding and (or) the velocity of its utilization. All of the mutants and the intact control were completely inactivated by both  $\beta$ -mercaptoethanol and deglycosylation treatments. This suggests that the four disulfide bonds play altogether a key role in maintaining catalytic function of these recombinant phytases (Ullah, A.H.J. et al., Biochem. Biophys. Res. Commun. 227:311-17 (1996), which is hereby incorporated by reference).

In conclusion, when the G helix and the GH loop do not contain the disulfide bond C200/C210 in Mutant U, the  $\alpha$ -domain may become slightly more flexible, resulting in a positive modulation on the catalytic efficiency and the thermostability of the enzyme. Because the *E. coli* phytase crystal structure will be released in the near future (Lim et al., Nat. Struct. Biol. 7:108-13 (2000), which is hereby incorporated by reference), more targeted mutagenesis studies should

- 35 -

shed light on conformational changes that may improve the properties of the enzyme.

Although preferred embodiments have been depicted and described in detail herein, it will be apparent to those skilled in the relevant art that various  
5 modifications, additions, substitutions, and the like can be made without departing from the spirit of the invention and these are therefore considered to be within the scope of the invention as defined in the claims which follow.

**WHAT IS CLAIMED:**

1. An isolated mutant acid phosphatase/phytase produced by making a plurality of amino acid substitutions in a wild-type *Escherichia coli* acid phosphatase/phytase having an amino acid sequence of SEQ. ID. No. 1, said amino acid substitutions comprising substitutions at positions 200, 207, and 211.
2. The isolated mutant acid phosphatase/phytase according to claim 1, wherein the amino acid substitution at position 200 is an Asn amino acid residue for a Cys amino acid residue, the amino acid substitution at position 207 is an Asn amino acid residue for an Asp amino acid residue, and the amino acid substitution at position 211 is an Asn amino acid residue for a Ser amino acid residue, said isolated mutant acid phosphatase/phytase having an amino acid sequence of SEQ. ID. No. 3.
3. The isolated mutant acid phosphatase/phytase according to claim 1, wherein the isolated mutant acid phosphatase/phytase is in pure form.
4. The isolated mutant acid phosphatase/phytase according to claim 1, wherein the isolated mutant acid phosphatase/phytase is recombinant.
5. A method for improving enzymatic properties of a wild-type *Escherichia coli* acid phosphatase/phytase having an amino acid sequence of SEQ. ID. No. 1, said method comprising:
  - altering the amino acid sequence of said wild-type acid phosphatase/phytase by introducing amino acid substitutions into SEQ. ID. No. 1 at positions 200, 207, and 211.
6. The method according to claim 5, wherein the amino acid substitution at position 200 is an Asn amino acid residue for a Cys amino acid residue, the amino acid substitution at position 207 is an Asn amino acid residue for an Asp amino acid residue, and the amino acid substitution at position 211 is an Asn amino acid residue for a Ser amino acid residue, said amino acid

- 37 -

substitutions resulting in a mutant acid phosphatase/phytase having an amino acid sequence of SEQ. ID. No. 3.

7. The method according to claim 5, wherein the improved enzymatic property is enhanced thermostability.

5 8. The method of claim 5, wherein the improved enzymatic property is greater phytase activity at a pH range of between about pH 3.5 to about pH 5.5.

9. An isolated DNA molecule encoding a mutant acid phosphatase/phytase according to claim 1.

10 10. The isolated DNA molecule according to claim 9, wherein the wild-type acid phosphatase/phytase is isolated from *Escherichia coli*.

11. The isolated DNA molecule according to claim 10, wherein the DNA molecule comprises a nucleotide sequence of SEQ. ID. No. 4 or hybridizes to a DNA molecule comprising the nucleotide sequence of SEQ. ID. No. 4 under stringency conditions comprising hybridization at 42°C in a hybridization medium comprising 5X SSPE and 50 percent formamide with washing at 50°C with 0.5X SSPE.

12. The isolated DNA molecule according to claim 9, wherein the amino acid substitution at position 200 is an Asn amino acid residue for a Cys amino acid residue, the amino acid substitution at position 207 is an Asn amino acid residue for an Asp amino acid residue, and the amino acid substitution at position 211 is an Asn amino acid residue for a Ser amino acid residue, said amino acid substitutions resulting in a mutant acid phosphatase/phytase having an amino acid sequence of SEQ. ID. No. 3.

13. A recombinant DNA expression system comprising a DNA molecule according to claim 9.

14. The expression system according to claim 13, wherein the DNA molecule is in a heterologous expression vector.

- 38 -

15. The expression system according to claim 13, wherein the DNA molecule is inserted into the expression system in proper orientation and correct reading frame.

16. A host cell comprising a heterologous DNA molecule  
5 according to claim 9.

17. The host cell according to claim 16, wherein said heterologous DNA molecule has the nucleotide sequence of SEQ. ID. No. 4.

18. The host cell according to claim 16, wherein said heterologous DNA molecule is in a recombinant DNA expression system.

10 19. The host cell according to claim 16, wherein said host cell is a yeast cell.

20. The host cell according to claim 19, wherein the yeast cell is of a strain selected from the group consisting of *Saccharomyces*, *Kluyveromyces*, *Torulaspora*, and *Schizosaccharomyces*.

15 21. The host cell according to claim 19, wherein the yeast cell is a methylotrophic yeast strain.

22. The host cell according to claim 21, wherein the methylotrophic yeast strain is selected from the group consisting of *Pichia*, *Hansenula*, *Torulopsis*, *Candida*, and *Karwinskia*.

20 23. A method of recombinantly producing a mutant acid phosphatase/phytase comprising:

transforming a host cell with at least one heterologous DNA molecule according to claim 9 under conditions suitable for expression of the mutant acid phosphatase/phytase and

25 isolating the mutant acid phosphatase/phytase.



- 39 -

24. The method according to claim 23, wherein the host cell is a yeast cell.

25. The method according to claim 24, wherein the yeast cell is of a strain selected from the group consisting of *Saccharomyces*, *Kluyveromyces*,  
5 *Torulaspora*, and *Schizosaccharomyces*.

26. The method according to claim 24, wherein the yeast cell is a methylotrophic yeast strain.

27. The host cell according to claim 26, wherein the methylotrophic yeast strain is selected from the group consisting of *Pichia*,  
10 *Hansenula*, *Torulopsis*, *Candida*, and *Karwinskia*.

28. An animal feed composition comprising the isolated mutant acid phosphatase/phytase according to claim 1.

29. A method for producing animal feed comprising:  
introducing the isolated mutant acid phosphatase/phytase  
15 according to claim 1 into animal feed under conditions effective to produce an animal feed composition.

30. An isolated mutant acid phosphatase/phytase which differs from a wild-type *Escherichia coli* acid phosphatase/phytase having an amino acid sequence of SEQ. ID. No. 1 by at least one amino acid substitution which disrupts  
20 disulfide bond formation between Cys amino acid residues at positions 200 and 210.

31. The isolated mutant acid phosphatase/phytase according to claim 30, wherein the isolated mutant acid phosphatase/phytase is in pure form.

32. The isolated mutant acid phosphatase/phytase according to  
25 claim 30, wherein the isolated mutant acid phosphatase/phytase is recombinant.

- 40 -

33. A method for improving enzymatic properties of a wild-type *Escherichia coli* acid phosphatase/phytase having an amino acid sequence of SEQ. ID. No. 1, said method comprising:

5 altering the amino acid sequence of said wild-type acid phosphatase/phytase by introducing at least one amino acid substitution which disrupts disulfide bond formation between Cys amino acid residues at positions 200 and 210.

34. The method according to claim 33, wherein the improved enzymatic property is enhanced thermostability.

10 35. The method of claim 33, wherein the improved enzymatic property is greater phytase activity at a pH range of between about pH 3.5 to about pH 5.5.

36. An isolated DNA molecule encoding a mutant acid phosphatase/phytase according to claim 30.

15 37. A recombinant DNA expression system comprising a DNA molecule according to claim 36.

38. The expression system according to claim 37, wherein the DNA molecule is in a heterologous expression vector.

20 39. The expression system according to claim 37, wherein the DNA molecule is inserted into the expression system in proper orientation and correct reading frame.

40. A host cell comprising a heterologous DNA molecule according to claim 36.

25 41. The host cell according to claim 40, wherein said heterologous DNA molecule is in a recombinant DNA expression system.

42. The host cell according to claim 40, wherein said host cell is a yeast cell.

- 41 -

43. The host cell according to claim 42, wherein the yeast cell is of a strain selected from the group consisting of *Saccharomyces*, *Kluyveromyces*, *Torulaspora*, and *Schizosaccharomyces*.

44. The host cell according to claim 42, wherein the yeast cell  
5 is a methylotrophic yeast strain.

45. The host cell according to claim 44, wherein the methylotrophic yeast strain is selected from the group consisting of *Pichia*, *Hansenula*, *Torulopsis*, *Candida*, and *Karwinskia*.

46. A method of recombinantly producing a mutant acid  
10 phosphatase/phytase comprising:

transforming a host cell with at least one heterologous DNA molecule according to claim 36 under conditions suitable for expression of the mutant acid phosphatase/phytase and

isolating the mutant acid phosphatase/phytase.

47. The method according to claim 46, wherein the host cell is  
15 a yeast cell.

48. The method according to claim 47, wherein the yeast cell is of a strain selected from the group consisting of *Saccharomyces*, *Kluyveromyces*, *Torulaspora*, and *Schizosaccharomyces*.

49. The method according to claim 47, wherein the yeast cell is  
20 a methylotrophic yeast strain.

50. The host cell according to claim 49, wherein the methylotrophic yeast strain is selected from the group consisting of *Pichia*, *Hansenula*, *Torulopsis*, *Candida*, and *Karwinskia*.

51. An animal feed composition comprising the isolated mutant  
25 acid phosphatase/phytase according to claim 30.

- 42 -

52. A method for producing animal feed comprising:

introducing the isolated mutant acid phosphatase/phytase  
according to claim 30 into animal feed under conditions effective to produce an  
animal feed composition.

1/4

1	taaggagcagaaaca	ATG TGG TAT TTA CTT TGG TTC GTC GGC ATT TTG TTG ATG TGT TCG CTC	63
1		M W Y L L W F V G I L L M C S L	16
64	TCC ACC CTT GTG TTG GTA TGG CTG GAC CCG CGA TTG AAA AGT Taacgaacgtaggcctgatgcggcg		128
17	S T L V L V W L D P R L K S *		31
129	cattagcatcgcacaggaatcaataatgtcagatatgaaaagcggaaacatatcgATG AAA GCG ATC TTA ATC		201
1		M K A I L I	6
202	CCA TTT TTA TCT CTT CTG ATT CCG TTA ACC CCG CAA TCT	E2	261
7	P F L S L L I P L T P Q S	A F A Q S E P	26
262	GAG CTG AAG CTG GAA AGT GTG GTG ATT GTC AGC CGT CAT GGT GTG CGT GCC CCA ACC AAG		321
27	E L K L E S V V I V S R H G V R A P T K		46
322	GCC ACG CAA CTG ATG CAG GAT GTC ACC CCA GAC GCA TGG CCA ACC TGG CCG GTA AAA CTG		381
47	A T Q L M Q D V T P D A W P T W P V K L		66
382	GGT TGG CTG ACA CCA CGC GGT GGT GAG CTA ATC GCC TAT CTC GGA CAT TAC CAA CGC CAG		441
67	G W L T P R G G E L I A Y L G H Y Q R Q		86
442	CGT CTG GTG GCC GAC GGA TTG CTG GCG AAA AAG GGC TGC CCG CAG CCT GGT CAG GTC GCG		501
87	R L V A D G L L A K K G C P Q P G Q V A		106
502	ATT ATT GCT GAT GTC GAC GAG CGT ACC CGT AAA ACA GGC GAA GCC TTC GCC GCC GGG CTG		561
107	I I A D V D E R T R K T G E A F A A G L		126
562	GCA CCT GAC TGT GCA ATA ACC GTA CAT ACC CAG	A1	621
127	A P D C A I T Y H T Q A D T S S P D P L		146
622	TTT AAT CCT CTA AAA ACT GGC GTT TGC CAA CTG GAT AAC GCG AAC GTG ACT GAC GCG ATC		681
147	F N P L K T G V C Q L D N A N V T D A I		166
682	CTC AGC AGG GCA GGA GGG TCA ATT GCT GAC TTT ACC GGG CAT CGG CAA ACG GCG TTT CGC		741
167	L S R A G G S I A D F T G H R Q T A F R		186
742	GAA CTG GAA CGG GTG CTT AAT TTT CCG CAA	P2	801
187	E L E R V L N F P Q S	TCA AAC TTG TGC CTT AAA CGT GAG AAA CAG	206
802	GAC GAA AGC TGT TCA TTA ACG CAG GCA TTA CCA TCG GAA CTC AAG GTG AGC GCC GAC AAT	P3	861
207	D E S C S L T Q A L P S E L K V S A D N		226
862	GTT TCA TTA ACC GGT GCG GTA AGC CTC GCA TCA ATG CTG ACG GAA ATA TTT CTC CTG CAA		921
227	V S L T G A V S L A S M L T E I F L L Q		246
922	CAA GCA CAG GGA ATG CCG GAG CCG GGG TGG GGA AGG ATC ACT GAT TCA CAC CAG TGG AAC		981
247	Q A Q G M P E P G W G R I T D S H Q W N		266
982	ACC TTG CTA AGT TTG CAT AAC GCG CAA TTT TAT TTA CTA CAA CGC ACG CCA GAG GTT GCC		1041
267	T L L S L H N A Q F Y L L Q R T P E V A		286
1042	CGC AGT CGC GCC ACC CCG TTA TTG GAT TTG ATC AAG ACA GCG TTG ACG CCC CAT CCA CCG		1101
287	R S R A T P L L D L I K T A L T P H P P		306
1102	CAA AAA CAG GCG TAT GGT GTG ACA TTA CCC ACT TCA GTG CTG TTT ATT GCC GGA CAC GAT		1161
307	Q K Q A Y G V T L P T S V L F I A G H D		326
1162	ACT AAT CTG GCA AAT CTC GGC GGC GCA CTG GAG CTC AAC TGG ACG CTT CCA GGT CAG CCG		1221
327	T N L A N L G G A L E L N W T L P G Q P		346
1222	GAT AAC ACG CCG CCA GGT GGT GAA CTG GTG TTT GAA CGC TGG CGT CGG CTA AGC GAT AAC		1281
347	D N T P P G G E L V F E R W R R L S D N		366
1282	AGC CAG TGG ATT CAG GTT TCG CTG GTC TTC CAG ACT TTA CAG CAG ATG CGT GAT AAA ACG		1341
367	S Q W I Q V S L V F Q T L Q Q M R D K T		386
1342	CCG CTA TCA TTA AAT ACG CCG CCC GGA GAG GTG AAA CTG ACC CTG GCA GGA TGT GAA GAG		1401
387	P L S L N T P P G E V K L T L A G C E E		406
1402	CGA AAT GCG CAG GGC ATG TGT TCG TTG GCC GGT TTT ACG CAA ATC GTG AAT GAA GCG CGC		1461
407	R N A Q G M C S L A G F T Q I V N E A R		426
1462	ATA CCG	K2	1491
427	I P A C S L *		433

FIGURE 1

2/4




FIGURE 2

3/4




FIGURE 3



4/4




FIGURE 4

## SEQUENCE LISTING

&lt;110&gt; Cornell Research Foundation, Inc.

&lt;120&gt; SITE-DIRECTED MUTAGENESIS OF ESCHERICHIA COLI PHYTASE

&lt;130&gt; 19603/4032

&lt;140&gt;

&lt;141&gt;

&lt;150&gt; 60/166,179

&lt;151&gt; 1999-11-18

&lt;160&gt; 9

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 432

&lt;212&gt; PRT

&lt;213&gt; Escherichia coli

&lt;400&gt; 1

Met	Lys	Ala	Ile	Leu	Ile	Pro	Phe	Leu	Ser	Leu	Leu	Ile	Pro	Leu	Thr
1				5					10					15	

Pro	Gln	Ser	Ala	Phe	Ala	Gln	Ser	Glu	Pro	Glu	Leu	Lys	Leu	Glu	Ser
			20					25					30		

Val	Val	Ile	Val	Ser	Arg	His	Gly	Val	Arg	Ala	Pro	Thr	Lys	Ala	Thr
		35					40					45			

Gln	Leu	Met	Gln	Asp	Val	Thr	Pro	Asp	Ala	Trp	Pro	Thr	Trp	Pro	Val
	50					55					60				

Lys	Leu	Gly	Trp	Leu	Thr	Pro	Arg	Gly	Gly	Glu	Leu	Ile	Ala	Tyr	Leu
65					70					75					80

Gly	His	Tyr	Gln	Arg	Gln	Arg	Leu	Val	Ala	Asp	Gly	Leu	Leu	Ala	Lys
			85						90					95	

Lys	Gly	Cys	Pro	Gln	Pro	Gly	Gln	Val	Ala	Ile	Ile	Ala	Asp	Val	Asp
			100				105						110		

Glu	Arg	Thr	Arg	Lys	Thr	Gly	Glu	Ala	Phe	Ala	Ala	Gly	Leu	Ala	Pro
		115					120						125		

Asp Cys Ala Ile Thr Val His Thr Gln Ala Asp Thr Ser Ser Pro Asp  
 130 135 140

Pro Leu Phe Asn Pro Leu Lys Thr Gly Val Cys Gln Leu Asp Asn Ala  
 145 150 155 160

Asn Val Thr Asp Ala Ile Leu Ser Arg Ala Gly Gly Ser Ile Ala Asp  
 165 170 175

Phe Thr Gly His Arg Gln Thr Ala Phe Arg Glu Leu Glu Arg Val Leu  
 180 185 190

Asn Phe Pro Gln Ser Asn Leu Cys Leu Lys Arg Glu Lys Gln Asp Glu  
 195 200 205

Ser Cys Ser Leu Thr Gln Ala Leu Pro Ser Glu Leu Lys Val Ser Ala  
 210 215 220

Asp Asn Val Ser Leu Thr Gly Ala Val Ser Leu Ala Ser Met Leu Thr  
 225 230 235 240

Glu Ile Phe Leu Leu Gln Gln Ala Gln Gly Met Pro Glu Pro Gly Trp  
 245 250 255

Gly Arg Ile Thr Asp Ser His Gln Trp Asn Thr Leu Leu Ser Leu His  
 260 265 270

Asn Ala Gln Phe Tyr Leu Leu Gln Arg Thr Pro Glu Val Ala Arg Ser  
 275 280 285

Arg Ala Thr Pro Leu Leu Asp Leu Ile Lys Thr Ala Leu Thr Pro His  
 290 295 300

Pro Pro Gln Lys Gln Ala Tyr Gly Val Thr Leu Pro Thr Ser Val Leu  
 305 310 315 320

Phe Ile Ala Gly His Asp Thr Asn Leu Ala Asn Leu Gly Gly Ala Leu  
 325 330 335

Glu Leu Asn Trp Thr Leu Pro Gly Gln Pro Asp Asn Thr Pro Pro Gly  
 340 345 350

Gly Glu Leu Val Phe Glu Arg Trp Arg Arg Leu Ser Asp Asn Ser Gln  
 355 360 365

Trp Ile Gln Val Ser Leu Val Phe Gln Thr Leu Gln Gln Met Arg Asp  
 370 375 380

Lys Thr Pro Leu Ser Leu Asn Thr Pro Pro Gly Glu Val Lys Leu Thr  
 385 390 395 400

Leu Ala Gly Cys Glu Glu Arg Asn Ala Gln Gly Met Cys Ser Leu Ala  
 405 410 415

Gly Phe Thr Gln Ile Val Asn Glu Ala Arg Ile Pro Ala Cys Ser Leu  
 420 425 430

<210> 2

<211> 1486

<212> DNA

<213> Escherichia coli

<400> 2

```

taaggagcag aaacaatgtg gtatttactt tggttcgtcg gcattttggt gatgtgttcg 60
ctctccaccc ttgtgttggt atggctggac ccgcgattga aaagttaacg aacgtaggcc 120
tgatgcggcg cattagcatc gcatacggca atcaataatg tcagatatga aaagcggaaa 180
catatcgatg aaagcgatct taatcccatt tttatctctt ctgattccgt taaccccgcgca 240
atctgcattc gctcagagtg agccggagct gaagctggaa agtgtggtga ttgtcagccg 300
tcatggtgtg cgtgccccaa ccaaggccac gcaactgatg caggatgtca cccagacgc 360
atggccaacc tggccggtaa aactgggttg gctgacacca cgcggtggtg agctaactgc 420
ctatctcgga cattaccaac gccagcgtct ggtggccgac ggattgctgg cgaaaaaggg 480
ctgcccgcag cctggtcagg tcgcgattat tgtcgatgtc gacgagcgta cccgtaaaac 540
aggcgaagcc ttcgcccgcg ggctggcacc tgactgtgca ataaccgtac ataccaggc 600
agatacgtcc agtcccgatc cgttatttat tcctctaaaa actggcgttt gccaaactgga 660
taacgcgaac gtgactgacg cgatcctcag cagggcagga gggtaattg ctgactttac 720
cgggcatcgg caaacggcgt ttcgcgaact ggaacgggtg cttaattttc cgcaatcaaa 780
cttgtgcctt aaacgtgaga aacaggacga aagctgttca ttaacgcagg cattaccatc 840
ggaactcaag gtgagcgccg acaatgtttc attaaccggt gcggttaagc tcgcatcaat 900
gctgacggaa atatttctcc tgcaacaagc acagggaatg ccggagccgg ggtggggaag 960
gatcactgat tcacaccagt ggaacacctt gctaagtttg cataacgcgc aattttat 1020
actacaacgc acgccagagg ttgcccgcag tcgcgccacc ccgttattgg atttgatcaa 1080
gacagcgttg acgccccatc caccgcaaaa acaggcgtat ggtgtgacat taccacttc 1140
agtgctgttt attgccggac acgatactaa tctggcaaat ctcggcggcg cactggagct 1200
caactggacg cttccaggtc agccggataa cacgccgcca ggtggtgaac tgggtgttga 1260
acgctggcgt cggctaagcg ataacagcca gtggattcag gtttcgctgg tcttccagac 1320
tttacagcag atgcgtgata aaacgccgct atcattaaat acgccgcccg gagagggtgaa 1380
actgaccctg gcaggatgtg aagagcgaaa tgcgcagggc atgtgttcgt tggccgggtt 1440
tacgcaaata gtgaatgaag cgcgcatacc ggcgtgcagt ttgtaa 1486

```

<210> 3

<211> 432

&lt;212&gt; PRT

&lt;213&gt; Escherichia coli

&lt;400&gt; 3

```

Met Lys Ala Ile Leu Ile Pro Phe Leu Ser Leu Leu Ile Pro Leu Thr
  1             5             10             15

Pro Gln Ser Ala Phe Ala Gln Ser Glu Pro Glu Leu Lys Leu Glu Ser
      20             25             30

Val Val Ile Val Ser Arg His Gly Val Arg Ala Pro Thr Lys Ala Thr
      35             40             45

Gln Leu Met Gln Asp Val Thr Pro Asp Ala Trp Pro Thr Trp Pro Val
      50             55             60

Lys Leu Gly Trp Leu Thr Pro Arg Gly Gly Glu Leu Ile Ala Tyr Leu
      65             70             75             80

Gly His Tyr Gln Arg Gln Arg Leu Val Ala Asp Gly Leu Leu Ala Lys
      85             90             95

Lys Gly Cys Pro Gln Pro Gly Gln Val Ala Ile Ile Ala Asp Val Asp
      100             105             110

Glu Arg Thr Arg Lys Thr Gly Glu Ala Phe Ala Ala Gly Leu Ala Pro
      115             120             125

Asp Cys Ala Ile Thr Val His Thr Gln Ala Asp Thr Ser Ser Pro Asp
      130             135             140

Pro Leu Phe Asn Pro Leu Lys Thr Gly Val Cys Gln Leu Asp Asn Ala
      145             150             155             160

Asn Val Thr Asp Ala Ile Leu Ser Arg Ala Gly Gly Ser Ile Ala Asp
      165             170             175

Phe Thr Gly His Arg Gln Thr Ala Phe Arg Glu Leu Glu Arg Val Leu
      180             185             190

Asn Phe Pro Gln Ser Asn Leu Asn Leu Lys Arg Glu Lys Gln Asn Glu
      195             200             205

Ser Cys Asn Leu Thr Gln Ala Leu Pro Ser Glu Leu Lys Val Ser Ala
      210             215             220

Asp Asn Val Ser Leu Thr Gly Ala Val Ser Leu Ala Ser Met Leu Thr
      225             230             235             240

```

Glu Ile Phe Leu Leu Gln Gln Ala Gln Gly Met Pro Glu Pro Gly Trp  
 245 250 255  
 Gly Arg Ile Thr Asp Ser His Gln Trp Asn Thr Leu Leu Ser Leu His  
 260 265 270  
 Asn Ala Gln Phe Tyr Leu Leu Gln Arg Thr Pro Glu Val Ala Arg Ser  
 275 280 285  
 Arg Ala Thr Pro Leu Leu Asp Leu Ile Lys Thr Ala Leu Thr Pro His  
 290 295 300  
 Pro Pro Gln Lys Gln Ala Tyr Gly Val Thr Leu Pro Thr Ser Val Leu  
 305 310 315 320  
 Phe Ile Ala Gly His Asp Thr Asn Leu Ala Asn Leu Gly Gly Ala Leu  
 325 330 335  
 Glu Leu Asn Trp Thr Leu Pro Gly Gln Pro Asp Asn Thr Pro Pro Gly  
 340 345 350  
 Gly Glu Leu Val Phe Glu Arg Trp Arg Arg Leu Ser Asp Asn Ser Gln  
 355 360 365  
 Trp Ile Gln Val Ser Leu Val Phe Gln Thr Leu Gln Gln Met Arg Asp  
 370 375 380  
 Lys Thr Pro Leu Ser Leu Asn Thr Pro Pro Gly Glu Val Lys Leu Thr  
 385 390 395 400  
 Leu Ala Gly Cys Glu Glu Arg Asn Ala Gln Gly Met Cys Ser Leu Ala  
 405 410 415  
 Gly Phe Thr Gln Ile Val Asn Glu Ala Arg Ile Pro Ala Cys Ser Leu  
 420 425 430

&lt;210&gt; 4

&lt;211&gt; 1486

&lt;212&gt; DNA

&lt;213&gt; Escherichia coli

&lt;400&gt; 4

taaggagcag aaacaatgtg gtatttactt tggttcgctcg gcattttggtt gatgtgttcg 60

```

ctctccaccc ttgtgttggt atggctggac ccgcgattga aaagttaacg aacgtaggcc 120
tgatgcggcg cattagcatc gcatcaggca atcaataatg tcagatatga aaagcggaaa 180
catatcgatg aaagcgatct taatcccatt tttatctctt ctgattccgt taaccCcgca 240
atctgcattc gctcagagtg agccggagct gaagctggaa agtgtggtga ttgtcagccg 300
tcatggtgtg cgtgccccaa ccaaggccac gcaactgatg caggatgtca ccccaGacgc 360
atggccaacc tggccggtaa aactgggttg gctgacacca cgcggtggtg agctaatcgc 420
ctatctcgga cattaccaac gccagcgtct ggtggccgac ggattgctgg cgaaaaaggg 480
ctgcccgcag cctggtcagg tcgcgattat tgtcgatgtc gacgagcgta cccgtaaaaac 540
aggcgaagcc ttcgccgccg ggctggcacc tgactgtgca ataaccgtac ataccCaggc 600
agatacgtcc agtcccgatc cgttatztat tctctataaa actggcgttt gccaaCtgga 660
taacgcgaac gtgactgacg cgatcctcag cagggcagga gggTcaattg ctgactttac 720
cgggcacgag caaacggcgt ttcgcgaact ggaacgggtg cttaattttc cgcaatcaaa 780
cttgaacctt aaacgtgaga aacagaatga aagctgtaac ttaacgcagg cattaCcatc 840
ggaactcaag gtgagcgccg acaatgtttc attaaccggt gcggtaagcc tcgcatcaat 900
gctgacggaa atattttctc tgcaacaagc acagggaatg ccggagccgg ggtggggaag 960
gatcactgat tcacaccagt ggaacacctt gctaagtttg cataacgcgc aattttatatt 1020
actacaacgc acgccagagg ttgcccgcag tcgcgccacc ccgttattgg atttgatcaa 1080
gacagcgttg acgccccatc caccgcaaaa acaggcgatg ggtgtgacat taccacttc 1140
agtgtgtttt attgccggac acgatactaa tctggcaaat ctggcgggcg cactggagct 1200
caactggacg cttccaggtc agccggataa cacgccgcca ggtggtgaac tgggtgtttga 1260
acgctggcgt cggctaagcg ataacagcca gtggattcag gtttcgctgg tcttcCagac 1320
tttacagcag atgcgtgata aaacgccgct atcattaaat acgccgcccg gagaggtgaa 1380
actgaccctg gcaggatgtg aagagcgaaa tgcgcagggc atgtgttcgt tggccgggtt 1440
tacgcaaate gtgaatgaag cgcgcatacc ggcgtgcagt ttgtaa 1486

```

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
Oligonucleotide

<400> 5

ggaattcgct cagagccgga

20

<210> 6

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
Oligonucleotide



&lt;400&gt; 6

ctgggtatgg ttggttatat tacagtcagg t

31

&lt;210&gt; 7

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:  
Oligonucleotide

&lt;400&gt; 7

caaacttgaa ccttaaactg gag

23

&lt;210&gt; 8

&lt;211&gt; 31

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:  
Oligonucleotide

&lt;400&gt; 8

cctgcgttaa gttacagctt tcattctggt t

31

&lt;210&gt; 9

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:  
Oligonucleotide

&lt;400&gt; 9

ggggtacctt acaaactgca cg

22

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/31622

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 9/12, 1/20, 15/00; C12Q 1/68; C07H 21/04

US CL : 435/6, 194, 252.3, 320.1; 536/23.2, 23.7

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 194, 252.3, 320.1; 536/23.2, 23.7

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Extra Sheet.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHIARUGI et al. Differential role of four cyateines on the activity of a low Mr phosphotyrosine protein phosphatase. FEBS LETTERS. 21 September 1992, Vol. 310, No. 1. pages 9-12, see the entire document.	1-52
A	LIM et al. Crystal structure of Escherichia coli phytase and its complex with phytate. Nature Structural Biology. February 2000, Vol. 7, No. 2. pages 108-113, see the entire document.	1-52

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 23 MARCH 2001	Date of mailing of the international search report 16 APR 2001
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer TERRY J. DEY PARALEGAL SPECIALIST TECHNOLOGY CENTER 1800 TEKCHAND SAIDHA Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/31622

## B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

West and STN files including medline, Caplus, Embase, Biosis and Biotechds. Search terms included - (acid phosphatase or phytase) and (nucleic acid or DNA or RNA) and Escherichia coli, and (mutant? or mutation? or variant?); etc. in different combinations.